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Abstract 
 
Prodrugs are pharmacologically inactive molecules which undergo metabolic bioactivation in vivo 
to form pharmaceutically active agents. Prodrugs have been designed to improve so called drug-
like properties of active parent compounds (APC) i.e. to increase solubility or absorption and to 
reduce first-pass metabolism etc. In this master’s thesis the goal was to establish non-cell-based in 
vitro methods to study prodrug bioactivation. 
 
Four commercially available prodrugs (bambuterol, olmesartan medoxomil (OM), candesartan 
cilexetil (CC) and famciclovir) were used as test compounds. The prodrugs were incubated in liver 
and intestinal S9 fractions and blood plasma to study in vitro bioactivation of these prodrugs. Other 
metabolism of the prodrug and APC (nonproductive metabolism) was studied by comparing 
incubation with and without cofactors of metabolizing enzymes. Species differences was studied 
using human, rat and dog matrices. Prodrug concentrations were quantified from the incubation 
samples using liquid chromatography- tandem mass spectrometry (LC-MSMS) methods developed 
for this study. Additionally the effect of promoiety on passive permeability was studied with parallel 
artificial membrane permeability assay (PAMPA). 
 
All of the studied prodrugs produced at least low concentrations of APC in one or more incubations. 
Terbutaline (APC of bambuterol) formation was observed in human plasma and was concentration 
dependent which is consisted with the literature. Olmesartan and candesartan were formed in S9 
fraction in high rate, but not in buffer: indicating enzyme mediated hydrolysis. However, based on 
literature CC hydrolysis was not expected to occur in intestinal S9 fractions. Penciclovir (APC of 
famciclovir) was formed only in presence of human or rat liver S9 fraction which was in line with 
the pre-existing literature. With the method used the nonproductive metabolism could not be 
estimated. In PAMPA bambuterol, famciclovir and OM had higher permeability than corresponding 
APCs whereas CC was only more permeable than candesartan in pH 7.4. 
 
The in vitro incubation used in this study can be used for screening prodrugs. However both low 
and high activation rates were observed thus the clinically relevant in vivo APC formation can be 
achieved with both high and low bioactivation in vitro. Studying the rate of prodrug formation alone 
estimations about clinically relevant bioactivation rates cannot be concluded. No clear signs of 
nonproductive could be seen with the prodrugs studied with current method. For the estimation of 
nonproductive metabolism, metabolite screening studies would need to be developed and conducted 
parallel to studies prescribed in this master’s thesis. 
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Literature review: 
 
 
1. INTRODUCTION: 
 
Prodrugs are generally defined as pharmacologically inactive chemical 
molecules which are transformed to pharmacologically active agents in vivo 
(Rautio et al. 2008; Huttunen et al. 2011). E.g. drugs which have active 
metabolites that contribute to therapeutic effect together with the parent 
compound are not prodrugs. Most of the currently marketed prodrugs are 
chemical derivatives of active agents with poor ADMET (Absorption, 
Distribution, Metabolism, Excretion and Toxicity) or physicochemical 
properties (Rautio et al. 2008). Prodrug strategy has thus been used to 
overcome difficulties in drug delivery and/or formulations. Estimated 15% of 
the drugs entering the market annually are prodrugs (Rautio et al. 2008; 
Müller 2009). 
 
If a group of potent parent compounds does not possess suitable drug-like 
properties the prodrug strategy can be introduced to overcome these 
difficulties (Rautio et al 2008). I.e. screening a series of different active 
compound/ promoiety combination is a possibility to enhance the drug-like 
properties. This way the screening of completely new molecules is not 
required. This can reduce the costs and time consumed in drug discovery. 
 
The simplest prodrugs consist of an active parent compound (APC), i.e. the 
drug-moiety, linked with a simple promoiety. Depending on the structure of 
the drug-moiety, the promoiety can be attached directly to the drug-moiety 
with chemical linkers such as ester, amide ester or with other linkers (Figure 
1A). Bioprecursor prodrugs are activated e.g. via enzymatic oxidation or 
reduction and no promoiety is detached in the activation process (Rautio 
2011). The antiplatelet aggregation drug, clopidogrel is an example of a 
bioprecursor prodrug (Figure 1B). Double prodrugs contain two promoieties 
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or they have to undergo two chemical or enzymatic reactions to form the APC 
(Rautio 2011). Also triple, quadruple etc. prodrugs exist. As an example an 
orally administrable bambuterol is a bis-dimethylcarbamate derivative and a 
double prodrug of bronchodilating agent terbutaline (Figure 1C). 
 
 
Figure 1. Four different types of prodrugs: Linker mediated prodrug 
fospropofol (A), bioprecursor clopidogrel (B), double prodrug bambuterol (C), 
and codrug sulfasalazine (D). 
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Prodrugs like sulfasalazine consist of two pharmacologically active molecules 
that are linked together (Figure 1D).  In the case of sulfasalazine the covalent 
linkage is cleaved in the colon by bacterial flora to form the two parent 
compounds: sulfapyridine and 5-aminosalisylic acid. Here both parent 
compounds act as a promoiety and as a drug-moiety and it’s referred as a 
codrug (Das et al 2010). The linkage between the two parent compounds in a 
codrug can also be direct or there can be a cleavable linker.  
 
The prodrug strategy of course has its limitations. First of all the chemical 
structure of the APC needs to possess a suitable site where the desired 
promoiety can be incorporated e.g. hydroxyl, phenyl, amine or carboxyl group 
(Rautio et al. 2008). The promoiety has to be cleavable at appropriate rate in 
vivo and it needs to occur in desired compartment(s) of the body. In addition 
prodrug and the promoiety have to be nontoxic and preferably biologically 
inactive (if codrug strategy is not intended). In safety point of view 
comprehension of the pharmacokinetic properties and toxicity of the prodrug, 
the promoiety and the APC are needed. Established knowledge of the 
enzymes involved in the prodrug activation is important as it helps in 
understanding of these properties. 
 
 
2. PRODRUG CLASSIFICATION 
 
Prodrugs have been classified according to several criteria e.g. the 
therapeutic target, the type of promoiety, the type of chemical linker (e.g. 
ester, amide ester etc.), the ADMET properties to overcome, or the site of 
activation (Wu 2009). The classification based on the site of activation 
consists of three major classes: intracellular (Type I) and extracellular 
activation (Type II) or both (mixed-type), which can be further divided to 
subtypes according the tissue where the biotransformation occurs (Table 1).  
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Table 1. Site specific classification system (modified from Wu 2009) 
Type 
Site of 
biotransformation 
Subtype 
Site of 
biotransformation 
Type I Intracellular 
IA Target tissue 
IB Metabolic tissues 
  IIA GI tract 
 
Type II 
 
 
Extracellular 
IIB 
Systemic circulation 
other extracellular 
fluids 
  IIC Target tissue 
 
 
Mixed-type 
 
 
Intra- and/or 
extracellular 
Parallel 
 
 
Sequential 
Simultaneous in 
multiple sites 
 
Sequential steps 
which occur in 
different sites 
Source: Wu 2009 
 
This classification is very informative and thus useful in drug development. 
Understanding the type of prodrug required to achieve desired change in 
ADMET properties is crucial in the development of prodrug derivatives. 
Moreover it gives information about pharmacokinetics of the prodrug and 
helps to detect efficacy and safety issues (Wu 2009). E.g. if prodrug strategy 
is introduced to improve poor bioavailability caused by high affinity for efflux 
transporters in the intestine, problems may arise if the promoiety is cleaved 
extensively in the enterocytes of the intestine. Another example if the active 
parent compound is known to have high first-pass metabolism in the liver, 
the goal would be to obtain prodrug that would mainly transform in other 
compartments such as plasma or the site of action to increase bioavailability. 
 
Mixed-type prodrugs belong to more than one class in this classification 
system (Wu 2009). This means that the biotransformation can occur in 
different compartments of the body. The mixed-type prodrugs are also further 
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divided to parallel and sequential types (Table 1). Biotransformation of 
parallel mixed-type prodrugs occurs simultaneously in more than one 
compartment e.g. in plasma and in liver. Sequential mixed-type prodrugs 
require several enzymatic steps to form the active parent drug. These steps 
may need to occur in specific sequence and in different compartments of the 
body. Due to their complicity mixed-type prodrugs are rarely ideal starting 
point for prodrug strategy. 
 
As prodrug strategy is often used to overcome problems with ADMET 
properties, the prodrugs here are discussed according to the classification 
based on the problem addressed with prodrug strategy. The site of activation 
based classification is considered as well using examples. 
 
 
3. IMPROVING AQUEOUS SOLUBILITY 
 
Aqueous solubility of drug molecules is a very important factor to be 
considered as only molecules that are soluble in biological medium are able 
to produce a biological effect. Depending on the route of administration the 
drug needs to be soluble in GI fluids or IV solutions etc. The basic principle 
in prodrug strategy of improving the solubility of drug molecules is to 
incorporate polar promoieties to poorly water soluble structures. (Müller 
2009). These polar promoieties include phosphates and amino acids. As amino 
acid derivatives can also facilitate better absorption via active transporters, 
they are discussed later. 
 
Phosphate promoieties can be incorporated A) directly to alcohol and phenol 
functions (fosamprenavir) B) via spacer (anesthetic fospropofol) or C) to an 
amide function such as an aromatic nitrogen (antiemetic fosaprepitant) 
(Figure 2). In general phosphate promoieties are cleaved by alkaline 
phosphatases (ALP, EC 3.1.3.1).  
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A)    B)             C)  
Figure 2. Examples of phosphate prodrugs: A) fosamprenavir B) fospropofol 
C) fosaprepitant. The red line indicates the site of cleavage. 
 
3.1 Phosphate prodrugs for intravenous administration 
 
Alkaline phosphatases are dephosphorylating enzymes distributed 
throughout the body as discussed in chapter 8.4 alkaline phosphatase 
(Goldstein et al. 1980; Moss 1982). The wide distribution of these enzymes 
enables the use of prodrug strategy when improving aqueous solubility for 
intravenous (IV) administration.  
 
Successful phosphate prodrugs for IV administration include e.g. fospropofol 
and fosaprepitant (Figure 2). Fospropofol is a spacer linked phosphate 
prodrug of the anesthetic propofol. The water solubility of fospropofol 
disodium is over 1000 times greater compared to the solubility of propofol 
(Müller 2009). After injection fospropofol is rapidly hydrolyzed by alkaline 
phosphatases (McIntosh and Rajewski 2012). Propofol exists also as an 
emulsion based formulation, but it is associated with pain in the injection 
site. The need of reduction of this side effect drove the development of water 
soluble prodrug of propofol. 
 
The oxymethyl linker between propofol and phosphate promoiety reduces 
steric hindrance making the prodrug more accessible to alkaline phosphatase 
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and thus it is more readily cleaved than a prodrug without linker 
(Kumpulainen et al. 2008).  In this case, addition to propofol and detached 
phosphate promoiety, also a formaldehyde molecule is formed in the 
activation process (Figure 3). Formaldehyde is further metabolized to formic 
acid. As both of these are toxic it raises concerns. However formic acid level 
above the physiological range has not been measured after fospropofol 
administration (Flechner et al. 2008). Alternative spacers for phosphate 
prodrugs have been discussed in the literature, but those have also been more 
chemically labile (Safadi et al. 1993; Kumpulainen et al. 2008). 
 
 
Figure 3. The scheme of fospropofol bioconversion to propofol  
 
An intravenous administration of fospropofol to dogs resulted similar plasma 
concentrations of propofol than emulsion based propofol IV formulation 
(McIntosh and Rajewski 2012). Due to the nature of the prodrug, the onset of 
pharmacological effect was slightly delayed and duration of action was 
slightly prolonged. In the case of fospropofol, smaller plasma concentration of 
propofol seemed to produce the same clinical effect. As propofol is highly 
bound to plasma proteins the authors presented that fospropofol displaces 
propofol from plasma proteins and thus the different Cplasma/response profile 
was due to higher unbound fraction of propofol.   
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The promoiety of IV administrated phosphate prodrugs is cleaved by alkaline 
phosphatases (ALPs) in plasma, liver, kidney and in other tissues, making 
them either prodrug class IIB, if activation occurs in plasma, or IB/IIB if the 
site of action is in metabolic tissues. As ALPs in various tissues have very 
similar substrate specificities, it is more likely that these prodrugs are 
hydrolyzed simultaneously in multiple tissues, making them parallel mixed-
type prodrugs. This needs to be considered when screening prodrug activation 
in vitro. The two main sites of dephosphorylation are plasma and liver (Rautio 
et al. 2008). Phosphate prodrugs with linker could also be classified to 
sequential mixed-type prodrugs, but since the second phase is often very 
rapid and spontaneous this seems unnecessary. 
 
3.2 Phosphate prodrugs for oral administration 
 
The oral administration for phosphate prodrugs have proven to be more 
challenging, as there are only few examples of oral phosphate prodrugs. 
Examples of marketed oral phosphate prodrugs are the HIV protease 
inhibitor fosamprenavir and estramustine phosphate for the treatment of 
prostate cancer (Figure 4). 
 
A)     B)  
Figure 4. Fosamprenavir (A) and estramustine phosphate (B) 
 
When considering oral drug delivery, one might expect the ionic phosphate 
promoieties to be unbeneficial for absorption. However, in this case, the 
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prodrug is rapidly transformed to APC by alkaline phosphatases (ALP) in the 
brush border of intestinal enterocytes prior to absorption (Heimbach et al. 
2003a; Stella and Nti-Addae 2007; Rautio et al. 2008). In general orally 
administered phosphate prodrugs are classified as type IIA as they are 
hydrolyzed by intestinal alkaline phosphatase in the gut lumen.  
 
Since phosphate prodrugs are highly polar, problems in absorption are 
expected if the cleavage of the promoiety is too slow. Additionally the cleavage 
of the phosphate promoiety can even be too extensive or fast leading to 
supersaturated solutions in gut lumen and finally to precipitation of the APC 
(Heimbach et al. 2003b). To avoid precipitation the APC have to possess high 
permeability. However if the dose is low, even a low solubility drug may 
dissolute completely within intestinal residence time and therefore prodrug 
approach is unnecessary (Heimbach et al. 2003a). Thus the phosphate 
prodrug strategy for oral formulations is most suitable for APCs that require 
relatively high dose and belong to class II (low solubility, high permeability) 
in biopharmaceutical classification system (BCS).  Heimbach et al (2007) 
demonstrated the use of dose number (Do) as a useful tool for finding 
appropriate candidates for solubility enhancing prodrug strategy. Dose 
number is calculated using equation 1: 
 
Do = dose/250ml/Csmin              (1) 
 
, where Csmin in mg/ml is the lowest solubility of APC at intestinal pH, the 
unit for dose is mg and 250ml is the volume of fluid intake recommended with 
oral administration of drugs.  Parent compound belonging to BCS class II and 
dose number >100 are the most suitable for this type of prodrug development 
(Heimbach et al. 2007). E.g. both amprenavir and estramustine (Figure 4) 
meet these requirements. 
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Amprenavir is the APC of fosamprenavir. Like the prodrug amprenavir itself 
is orally administered. Due to required high dose (1200mg) and the need of 
relatively high amounts of excipients, the dosing requires multiple capsules 
to be administered at once (Furfine et al. 2004). The target of discovering 
more soluble prodrug of amprenavir was originally to decrease the amount of 
dosing units and thus increasing patient compliance.   
 
Fosamprenavir is hydrolyzed to amprenavir in the intestinal lumen prior to 
absorption (Furfine et al. 2004). The prodrug was found to be a substrate of 
rat, dog and human alkaline phosphatase and the exposure to fosamprenavir 
was low in rats and dogs, compared to the exposure to the APC. 
Fosamprenavir is administered as calcium salt.  The solubility of the salt 
however is highly pH dependent. Solubility is good at acidic pH but is 
decreased significantly in neutral pH. This creates possibilities to drug 
interactions with antacids and PPIs. 
 
 
4. INCREASING ABSORPTION 
 
Before drugs reach their biological target (i.e. receptor, enzyme etc.), they 
need to cross several physiological barriers. Depending on the route of 
administration and target tissue these barrier include intestinal epithelium, 
BBB, corneal epithelium etc. In order to reach their targets these drugs 
usually need to be somewhat lipophilic as the barriers are mostly lipid based 
cell membranes. Masking polar groups of a drug molecule with promoiety is 
a possibility to improve passive permeability through these barriers (Rautio 
2011). However vital nutrients such as amino acids and vitamins are actively 
transported through these membranes. Exploiting these transporters 
presents another opportunity to bypass these membranes.  
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Drugs that belong to BCS class III possess high solubility and low 
permeability. These drugs have usually polar and/or ionic functionalities such 
as carboxyl, amide, phosphate or sulfate groups. Masking these 
functionalities decreases polarity of these molecules and is thus likely to 
increase passive permeability through intestinal wall (Rautio 2011). To 
successfully increase absorption, the prodrug needs to be stable in GI fluids 
and be transformed into the APC only after absorption.  Figure 5 and Table 2 
show examples of such prodrugs on the market.  
 
A)   B)  
C) D)  
Figure 5. Structures of prodrugs with masked polar functionalities, red line 
indicates the site of cleavage: A) ramipril B) dabigatran etexilate C) 
latanoprost D) famciclovir 
 
4.1 Permeability 
 
Compared to other problems addressed with prodrug strategy, the goal of 
increasing oral absorption by reducing the number of ionic functionalities and 
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hydrogen bond acceptors and donors has probably been the most successful. 
The amount of this type of prodrugs in the market is numerous (Table 2). 
 
Table 2. Examples of prodrugs with increased oral absorption. R = drug 
moiety 
Prodrug Promoiety Masked functionality Therapeutic area 
Ximelagatran 
Ethyl ester + 
N-reduction 
-COOH Antithrombotic 
Dabigatran 
etexilate 
(see Figure 5B) 
Ethyl ester + 
 
-COOH +  amidine Antithrombotic 
Famciclovir 
dicarboxylic ester + 
heterocyclic 
oxidation 
-OH 
Antiviral 
(Herpes simplex) 
Oseltamivir Ethyl ester -COOH Antiviral (influenza) 
Candesartan 
cilexetil  
-COOH 
Hypertension 
(ATR antagonist) 
Olmesartan 
medoxomil 
 
-COOH 
Hypertension 
(ATR antagonist) 
Enalapril, 
Perindropril, 
Ramipril 
Ethyl ester -COOH ACE-inhibitor 
Mycophenolate 
mofetil  
-COOH Immunosuppressant 
Latanoprost Isopropyl ester -COOH Glaucoma 
Simvastatin, 
Lovastatin 
Lactone ring -COOH and -OH Hypercholesterolemia 
 
4.1.1 Famciclovir 
 
Famciclovir is a very interesting prodrug of penciclovir (Figure 5D and 6). 
Penciclovir can be in fact considered as a prodrug itself as it requires 
phosphorylation and it is the triphosphate form of penciclovir that inhibits 
the replication of herpes simplex virus (Jarvest et al. 1998). Famciclovir also 
undergoes a three step activation to form penciclovir (Vere Hodge et al. 1989; 
Jarvest et al. 1998). So in a way famciclovir is not only double or triple 
prodrug, but a sextuple prodrug. 
 
13 
 
The metabolic pathway from famciclovir to penciclovir includes several steps 
(Figure 6). The hydrolysis of single ester promoiety results a chiral compound. 
The first deacetylation occurs mainly in intestine wall during absorption 
(Vera Hodge et al. 1993). Intestinal esterases preferably hydrolyze the ester 
in the position leading to S-enantiomer of desacetyl famciclovir.  
 
 
Figure 6. The major bioconversion pathway of famciclovir to penciclovir. 
Sources: Vera Hodge et al. 1989; Clarke et al. 1995. 
 
However liver possesses greater metabolic activity on famciclovir than 
intestine (Jarvest et al. 1998). Both acyl-promoieties are hydrolyzed in the 
liver and the 6-oxidation also occurs in liver. Using xanthine oxidase inhibitor 
allopurinol and aldehyde oxidase inhibitors menadione and isovanillin in 
vitro, the enzyme responsible for the oxidation step has been identified to be 
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aldehyde oxidase (EC 1.2.3.1), an enzyme expressed in hepatocytes (Clarke et 
al. 1995).  The rate limiting step for penciclovir formation is the oxidation step 
(Jarvest et al. 1998).  R-desacetyl famciclovir, diacylpenciclovir and R- and S-
monoacetylpenciclovir were also detected in minor amounts and so these 
metabolic steps also occur in different order. Thus the scheme presented in 
Figure 6 represents only the major activation pathway. Based on these data 
famciclovir is classified as a sequential mixed-type prodrug. Interestingly the 
metabolic steps occur also partly in different tissues (intestine and liver). 
Famciclovir activation is also studied in the experimental part of this master’s 
thesis. 
 
4.1.2 Olmesartan medoxomil and candesartan cilexetil 
 
Olmesartan medoxomil (OM) and candesartan cilexetil (CC) are ester 
prodrugs of their corresponding carboxylic acid APCs olmesartan and 
candesartan, respectively (Figure 7). Both drugs are antagonists of 
angiotensin receptor, and share clear structural similarities. However, the 
promoieties masking the ionisable carboxyl group differ vastly. 
 
In vitro OM is hydrolyzed in cytosolic fractions of liver, kidney and intestine 
of various species (Ishizuka et al. 2010; 2013), and in plasma (Ishizuka et al. 
2012). The enzyme responsible for bioactivation in plasma was recognized to 
be paraoxonase (PON, EC 3.1.8.1), which is also present in liver microsomal 
fraction as discussed later. The enzyme responsible for metabolic tissue 
bioactivation was characterized to be carboxymethylenebutenolidase homolog 
(CMBL, EC 3.1.1.45), a cytosolic enzyme expressed in liver, intestine and 
kidney of various species (Ishizuka et al. 2010).  
 
15 
 
A)      B)  
Figure 7. The structures of olmesartan medoxomil (A) and candesartan 
cilexetil (B). 
 
In the study by Ishizuka et al. (2013) the hydrolysis of OM was measured in 
intestinal, liver, kidney and lung cytosolic and microsomal fractions of 
various species, by determining the rate of olmesartan formation from 
olmesartan medoxomil (Figure 8). 
 
Bioactivation was observed to be higher in cytosolic fractions of human, 
mouse, dog and monkey than in the corresponding microsomal fractions 
(Figure 8). Consequently it is expected that hydrolytic activity would also be 
higher in S9 fraction than in microsomal fraction. An exception to this was 
rat: here significant amount of hydrolytic activity was also observed in liver 
and kidney microsomes (Ishizuka et al. 2013). Of the species used in this 
study, mouse and monkey intestinal cytosols exhibited similar bioactivation 
rates than human intestinal cytosols (Figure 8). The bioactivation was also 
observed in rat intestinal fractions, but not in dog. The bioactivation in liver 
fractions was lower in human and significantly higher in monkey than in 
other species. The study showed clear differences in OM hydrolysis between 
species and tissues in vitro. 
 
In vivo pharmacokinetic data indicates rapid hydrolysis of the promoiety 
(Laeis et al. 2001). When given to healthy male volunteers, no intact prodrug 
was observed in plasma (first time point 30 min). The data is consisted with 
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the in vitro studies described above and indicates rapid first-pass metabolic 
activation of OM in the intestine or possibly also in the plasma and liver. 
However the bioavailability of olmesartan after orally administered OM is 
only 29%, likely due to poor solubility and/or permeability issues. Based on 
this data OM would be parallel mixed type prodrug (intestine, plasma and 
liver), but since the hydrolysis is rapid also class IB (intracellular metabolic 
tissue activation) seems appropriate simplification. 
 
 
Figure 8. OM hydrolysis rates measured in cytosolic and microsomal fractions 
of various tissues and in different species. Hydrolytic activity in cytosolic 
fractions (A) and in microsomal fraction (B) expressed as nmol/min/mg of 
protein (Ishizuka et al. 2013) 
 
Despite the structural similarities between CC and OM (Figure 7), the 
bioactivation of these two drugs occur via different enzymes (Ishizuka et al. 
2013). Hydrolysis of CC occurs in both cytosolic and microsomal fractions of 
liver, lung and kidney in mouse, rat, monkey, dog and human (Figure 9). The 
rate of hydrolysis was higher in microsomal fractions than in cytosolic 
fractions. Of the species investigated dog and monkey liver fractions 
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possessed same kind of hydrolytic activity as corresponding human fractions, 
whereas hydrolysis in mouse and rat liver fractions was slower. 
 
 
Figure 9. The hydrolysis of candesartan cilexetil in cytosolic fractions (A) and 
in microsomal fractions (B). Hydrolytic activity is highest in monkey, dog and 
human liver microsomal fractions and no hydrolytic activity was observed in 
the intestinal subcellular fractions. From Ishizuka et al. 2013. 
 
In further study using recombinant human carboxylesterases: hCES1 and 
hCES2 (EC 3.1.1.1), the enzyme responsible for the hydrolysis of CC was 
identified as hCES1 (Ishizuka et al. 2013). The distribution of CESs is 
discussed later, but the rates of hydrolysis in different cell fractions in this 
study are consistent with the distribution of CES1. 
 
Like OM, CC has also been observed to be rapidly hydrolyzed during 
absorption in vivo (van Lier et al. 1997). The plasma concentrations of CC are 
very low compared to candesartan concentrations. Only trace amounts of CC 
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is able to avoid the first-pass metabolism intact. Thus CC is classified also as 
class IB prodrug.  
 
4.2 Active transport 
 
Another way to increase oral absorption is to target intestinal transporters 
with the prodrug strategy (Rautio et al. 2008). The physiological role of these 
transport proteins is to increase uptake of amino acids and other vital 
nutrients. In the scientific literature prodrug strategies have mainly been 
focused on oligopeptide transporters (PEPT). This transporter in the prodrug 
concept has been widely reviewed by Zhang et al. (2013) and will be discussed 
only briefly here. PEPT proteins transport various di- and tripeptides as well 
as numerous xenobiotics. I.e. amino acid esters or amide prodrugs can be used 
to increase active absorption via peptide transporters. 
 
Some amino acid derived prodrugs have been successfully marketed e.g. 
antiviral agents: valgancyclovir and valacyclovir (Figure 10) (Zhang et al. 
2013). The prefix “val” refers to amino acid valine. Introducing an amino acid 
promoiety to the structure of APC not only increases active absorption, but in 
theory may also increase the solubility of the APC and decrease first pass-
metabolism by masking metabolic hot spots (Zhang et al. 2013).  
 
Compared to acyclovir, the oral bioavailability of valacyclovir is 3 to 5 times 
higher in rat, monkey and human (Weller et al. 1993). Hydrolysis of 
valacyclovir occurs in intracellular compartment of intestinal enterocytes 
(Kim et al. 2003). The hydrolyzing enzyme was named as valacyclovirase, but 
is more commonly known as alpha-amino-acid esterase (EC 3.1.1.43). The 
enzyme has also been identified in rat liver (Kim et al. 2003). Valacyclovir is 
thus classified as type IB prodrug. 
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Figure 10. Structure of valacyclovir, a valine derivative of acyclovir. The red 
line indicates the site of cleavage. 
 
 
5. AVOIDING FIRST-PASS METABOLISM 
 
As discussed above the oral bioavailability of drug molecules is dependent on 
the solubility and absorption from the gastrointestinal tract. Additionally the 
absorbed drug molecules are exposed to metabolism in the GI wall and liver 
before reaching the systemic circulation. The intersubject variability has been 
reported to be higher with drugs that have relatively low bioavailability 
(Hellriegel et al. 1996). Therefore increasing bioavailability might also 
decrease intersubject variability. However the prodrug concept adds the 
variability of individual activation thus complicating matters. The fraction 
reaching the systemic circulation (F) can be described with equation 2 
(Rowland and Tozer 2009): 
 
𝐹 = 𝐹𝐴 𝑥 𝐹𝐺  𝑥 𝐹𝐻                   (2) 
 
𝐹𝐻 = 1 − 𝐸𝐻                 (3) 
 
, where FA is the fraction absorbed, FG is the fraction avoiding first-pass gut 
metabolism and FH is the fraction avoiding first-pass liver metabolism. FH can 
be defined with hepatic extraction ratio, EH (equation 3) (Rowland and Tozer 
2009). The first-pass metabolism can thus occur during absorption in the 
enterocytes, in liver after absorption or both. Either way the prodrug should 
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be relatively stable in the intestine and in liver. The well stirred model of 
hepatic clearance states that  
 
 E𝐻 =
fu𝑏 x 𝐶𝐿𝐼𝑛𝑡
Q𝐻 + fu𝑏 x 𝐶𝐿𝐼𝑛𝑡
              (4) 
 
, where fub is the fraction unbound in blood, CLint is the intrinsic 
hepatocellular clearance of the molecule and QH is the hepatic blood flow 
(Rowland and Tozer 2009). As hepatic blood flow is a biological quantity, it is 
therefore independent of the molecule in most cases and for a drug point of 
view can be considered here as a constant.  
 
From equation 4 it follows that by decreasing CLint and/or fub with prodrug 
strategy, it is possible to reduce hepatic extraction ratio and therefore 
increase FH to increase oral bioavailability. However if the prodrug has high 
intrinsic hepatic clearance and the dissolution rate of the molecule from blood 
components is assumed to be rapid, decrease in fub is not enough to decrease 
EH (Rowland and Tozer 2009). Figure 11 is based on equations 2-4 and 
represents possible biotransformation pathways of a prodrug during 
absorption. 
 
Other thing needed to be considered is the possible nonproductive metabolism 
of the prodrug. Although the promoiety can be used to mask a metabolic hot-
spot of the APC, it is still possible that the rate of APC formation is slow 
compared to other metabolism of the prodrug.  
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Figure 11. Prodrug biotransformation during absorption. Orange lines 
indicate movement of the prodrug or drug from one compartment to another. 
Prodrug bound to blood components can avoid liver metabolism (dashed 
orange line). The red lines are for unwanted metabolism during absorption 
and the green line for preferred metabolism. u = unbound, b = bound to blood 
components. 
 
A successful prodrug strategy to decrease presystemic metabolism must fulfill 
several requirements (Table 3). The fraction absorbed of the prodrug should 
be equal or better than of APCs. The prodrug should be relatively stable 
during absorption i.e. the Fg should be higher than in the case of APC (or as 
high if the intestinal first-pass of the APC metabolism is not problematic). 
Compared to the APC the hepatic CLint or both CLint and fub should be lower 
in the case of prodrug. To avoid further nonproductive drug metabolism the 
enzymes converting prodrug to its APC should be preferably located outside 
metabolic tissue i.e. in the plasma or the target tissue. Additionally, the 
bioactivation of prodrug should occur in sufficient rate to produce clinically 
relevant concentrations of APC.  
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Table 3. Requirements for successful prodrug strategy avoiding first-pass 
metabolism. 
Requirement FA Fg CLint Fub Preferred site of bioactivation 
APC X Y Z W - 
Prodrug ≥ X ≥ Y, >0.8 < Z ≤W IA, IIB, IIC, mixed type 
 
Not many examples exist of successful prodrug strategy to decrease first-pass 
metabolism. One such prodrug is bambuterol, a double carbamate ester 
prodrug of bronchodilator terbutaline (Figures 1 and 12). Bambuterol is 
hydrolyzed by butyrylcholinesterase (BuChE, EC 3.1.1.8) in blood (Tunek and 
Svensson 1988). The hydrolysis occurs in two steps: 1) bambuterol is 
hydrolyzed to monocarbamate intermediate and 2) the monocarbamate is 
hydrolyzed to terbutaline (Figure 12). 
 
 
Figure 12. The hydrolytic step in the formation of terbutaline from 
bambuterol. 
 
Tunek et al. (1988) investigated species differences in the rates of hydrolysis 
of bambuterol in vitro. Bambuterol has higher affinity to BuChE than the 
monocarbamate intermediate in most species. Thus when bambuterol is 
present mainly the monocarbamate intermediate is formed. Only when the 
bambuterol concentrations are low the monocarbamate starts to hydrolyze 
into terbutaline (Figure 13). Additionally interindividual variations in the 
rates of monocarbamate and terbutaline formation were observed especially 
in human and rabbit. The hydrolysis of the monocarbamate occurred in 
greater extent in rabbit blood. Unlike in other species, in rabbit the formation 
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of terbutaline was relatively high. Thus bambuterol hydrolysis in rabbit blood 
might be mediated via another enzyme or the monocarbamate intermediate 
has greater affinity to rabbit BuChE. 
 
Figure 13. Terbutaline and monocarbamate formation at different incubation 
concentrations of bambuterol in human plasma in vitro. Bambuterol (cross), 
monocarbamate (square) and terbutaline (circle). Only at lower 
concentrations terbutaline is formed (A). At incubation concentration of 289 
nM, no terbutaline is formed (B) (Tunek et al. 1988). 
 
Bambuterol also acts as an inhibitor for BuChE, thus inhibiting its own 
metabolism (Tunek and Svensson 1988). The inhibition was found to be 
noncompetitive and preincubation of bambuterol in human blood increased 
the degree of inhibition. The maximum inhibition was observed with over 20 
minutes preincubation with bambuterol before measuring the enzyme 
activity.  
 
The authors presented that during hydrolysis of bambuterol, the carbamate 
promoiety binds covalently to the serine in the catalytic triad of BuChE and 
this bond is only slowly hydrolyzed causing the inhibition (Tunek and 
Svensson 1988). This inhibition was suspected to be the reason why 
bambuterol degeneration and monocarbamate formation exhibited two 
phases: The initial high rate of hydrolysis and a slower rate of hydrolysis later 
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(Figure 13). Bambuterol biotransformation also occurs in other tissues than 
blood. In theory the same type of inhibition is possible for all carbamate ester 
prodrugs. 
 
 
6. TARGETED DRUG DELIVERY 
 
The prodrug strategy can also be used to target specific tissues. Systemically 
administrated drugs rarely exhibit such high tissue specificity that only the 
target tissue or organ would be affected. Unwanted pharmacological or 
toxicological effects outside the target tissue are a likely cause of drug related 
side effects. The drug delivery to the target site can be problematic, especially 
when the target site is in central nervous system. The prodrug strategy can 
be used to achieve site specific activation or to modify the distribution profile 
of the drug. 
 
6.1 Site specific activation 
 
In order to produce site specific activation, tissue specific activating enzymes 
are required (Rautio et al. 2008). These enzymes can be naturally expressed 
or e.g. of viral origin. The antiviral drugs for herpes, like previously discussed 
prodrug famciclovir and its APC penciclovir (Figure 6), are good examples of 
targeted prodrugs. Penciclovir is phosphorylated by viral thymidine kinase 
inside the infected cells and only very small concentrations of the active 
triphosphorylated penciclovir are found in uninfected cells (Jarvest et al. 
1998). Other antiviral prodrugs like acyclovir, valacyclovir, ganciclovir and 
valganciclovir are targeted prodrugs in the similar way. 
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6.1.1 Capecitabine 
 
Another example of targeted drug delivery is the anticancer prodrug 
capecitabine used in the treatment of breast cancer and various cancers of the 
GI tract (Miwa et al. 1998) (Figure 14). 5´-deoxy-5-fluorouridine (5´-dFUrd) is 
a prodrug of cytotoxic 5-fluorouracil (5-FU). Although the formation of 5-FU 
from 5´-dFUrd is higher in tumor tissues than in normal tissue, the oral 
administration of 5´-dFUrd causes e.g. gastrointestinal side-effect probably 
due to formation of 5-FU during absorption. Capecitabine was developed to 
reduce side-effects related to 5´-dFUrd.  
 
 
Figure 14. Bioactivation of capecitabine to 5-FU (Miwa et al. 1998). 
Carboxylesterases release 5´-dFCyd mainly in liver. Cytidine deaminase 
metabolizes 5´-dFCyd to 5´-dFUrd mostly in liver and in tumor tissues. 
Finally high thymidine phosphorylase activity in tumor cells produces 5-
fluorouracil (5-FU) 
 
Capecitabine undergoes 3-step activation to form 5-FU (Figure 14) (Miwa et 
al. 1998). Capecitabine is first hydrolyzed by carboxylesterases (CES, EC 
3.1.1.1) to 5´-deoxy-5-fluorocytidine (5´-dFCyd) in liver. Cytidine deaminase 
(EC 3.5.4.5) converts 5´-dFCyd to 5´-dFUrd in tumor and liver tissues. Apart 
from liver cytidine deaminase activity is higher in tumor tissues compared to 
corresponding normal tissues. The final activation step from 5´-dFUrd to 5-
26 
 
FU is mediated by thymidine phosphorylase (dThdPase, EC 2.4.2.4) also 
known as platelet derived endothelial cell growth factor. It is expressed 
significantly more in tumor tissues compared to normal tissues. 
 
In cytotoxicity studies with various tumor cell lines, capecitabine and 5´-
dFCyd were considerably less cytotoxic than of 5´-dFUrd and 5-FU (Miwa et 
al. 1998). Both 5´-dFUrd and 5-FU are cytotoxic although the latter is 
considerably more potent in most cancer cell lines in vitro. Capecitabine 
works well as a prodrug as no additional metabolites are observed in plasma 
except the intermediate metabolites leading to 5-FU and those found in 
plasma also after 5-FU administration. The bioactivation of capecitabine 
occurs mainly in two sites: in the liver (Ib) and in the target tissue (Ia). Since 
the steps are sequential, capecitabine can be considered as sequential mixed-
type prodrug. 
 
6.1.2 Enzyme prodrug therapies 
 
Unfortunately target tissue specific enzymes rarely exist. However, the use 
of Antibody-Directed Enzyme Prodrug Therapy (ADEPT) and Gene-Directed 
Enzyme Prodrug Therapy (GDEPT) have been explored as an alternative 
especially in cancer therapy (Dachs et al. 2005; Bagshawe 2006; Tietze and 
Krewer 2009). These therapies consist of three steps (Bagshawe 2006). The 
first step is the introduction of bioactivating enzyme into the target tissue. In 
ADEPT, a recombinant protein of exogenous enzyme and a monoclonal 
antibody is administered (Figure 15). The antibody part then recognizes and 
bounds to tissue specific antigens and thus concentrating the enzyme into the 
target tissue. Respectively in GDEPT the gene encoding an exogenous 
enzyme is delivered to target cell via vectors e.g. adenovirus or herpes simplex 
virus (Dachs et al. 2005) (Figure 15).  
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Figure 15. Schema of ADEPT and GDEPT (Modified from Bagshawe 2006). 
In ADEPT (above), an exogenous enzyme (green pentagon) is localized into 
the target tissue using antibodies (yellow sector). In GDEPT (below), a gene 
encoding an exogenous enzyme is transfected to target cells using viral 
vectors (brown heptagons). Transfected cells then begin to express the 
enzyme. After prodrug administration the APC is released in target tissue. 
The pharmacological effect is restricted to a small area, but not only 
transfected cells are affected. The released drug-moiety (yellow circle) 
diffuses also into the neighboring cells (called the bystander effect).  
 
The second step is to wait that the enzyme is localized into the target tissue 
and cleared from other compartments (Bagshawe 2006). Once the enzyme is 
in the target tissue a prodrug is administered. The design of the prodrug 
should be carried out so that the prodrug would not undergo bioactivation via 
endogenous enzymes and would thus only release the APC in the tissues 
where the exogenous enzyme is localized (Figure 15) 
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The enzyme prodrug therapies have also their limitations. In terms of cancer 
therapy it was recognized that the APC should have relatively short half-life, 
or otherwise it would spread from the target site to other tissues via blood 
circulation (Bagswahe 2006). The immunogenic response is also expected and 
limiting the use of exogenous enzymes. However, the use of non-human 
enzymes is the best way to produce desired tissue specificity since they are 
not normally expressed in human tissues. Furthermore the immunogenicity 
is not necessarily a bad think as it might evoke immunologic response 
towards the tumor itself (Dachs et al. 2005). E.g. Bacterial enzymes 
carboxypeptidase G2 (EC: 3.4.17.11) and β-lactamase (EC: 3.5.2.6) have been 
utilized in clinical trials of ADEPT (Bagswahe 2006). 
 
6.2 Targeting central nervous system 
 
As discussed earlier, the prodrug strategies have successfully utilized 
transporters to increase oral absorption of drugs. In addition to GI tract 
transporter proteins like large neutral amino acid transporter (LAT1) and 
glucose carrier GluT1 are expressed e.g. in the blood brain barrier (BBB) 
(Gynther 2009 and 2010). Targeting these transporters has been studied as a 
possibility to target central nervous system. 
 
Gynther et al. (2008 and 2010) evaluated the brain uptake of several amino 
acid conjugated prodrugs of ketoprofen. Prodrugs where ketoprofen moiety 
was attached to the side chain of the amino acid (Figure 16) were able to cross 
the BBB. Thus it seems that targeting LAT1 requires free α-amino and 
carboxyl group (Gynther et al. 2008). 
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Figure 16. Stuctures of two prodrugs of ketoprofen. The promoieties are L-
lysine (a) and L-Tyrosine (b) are marked red (Gynther et al 2008 and 2010). 
 
Of the two prodrugs presented in Figure 16, the L-tyrosine prodrug was too 
labile in biological matrices and L-lysine derivate failed to increase free 
ketoprofen concentration in rat brain in vivo (Gynther et al 2008 and 2010). 
However, the authors concluded that LAT1 targeted prodrugs might serve as 
an alternative for increasing lipophilicity of lead molecule in order to achieve 
sufficient brain concentrations of the drug (Gynther et al. 2010).    
 
 
7. CODRUGS 
 
As discussed earlier codrugs consist of two active molecules each acting as a 
pro-moiety to the other (Das et al. 2010). The codrug strategy has been used 
to achieve various goals. These include e.g. increased absorption (oral, 
transdermal or ocular) and site specific activation. Additional benefit of the 
prodrug strategy is that the two active pharmaceutical compounds 
simultaneous reach their mutual target site. This is especially important if 
the drugs have synergic pharmacological effect. 
 
Ghosh et al. (2013) reported an interesting codrug approach to enable 
sustained release of naltrexone across the skin. Naltrexone is a µ-opioid 
receptor antagonist used for the treatment of alcoholism (Figure 17A). Issues 
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associated with current formulations lead the authors to investigate 7 days 
sustained release patch formulation through the skin. Naltrexone, however, 
is not able to diffuse through skin as such. Pretreating the skin with 
microneedles produce micropores through which more polar and bigger 
molecules (such as naltrexone) are also able to diffuse. However micropores 
begin to heal within 48-72 hours under occlusion and even faster when 
exposed to air. 
 
Previously diclofenac, a non-steroid anti-inflammatory drugs (NSAID), had 
been reported to prevent micropores from closing (Figure 17B) (Banks et al. 
2011). Due to different physicochemical properties of naltrexone and 
diclofenac coformulation of the drugs was found to be problematic and thus 
the authors started to investigate a codrug of these two drugs (Figure 17C) 
(Ghosh et al. 2013). In this study, micropores were first formed by pressing 
twice an array of 50 microneedles to hairless guinea pig skin (100 pores in 
total) and placing a reservoir patch containing the codrug over the 
microneedle treated skin. 
 
The prodrug had relatively short half-life in hairless guinea pig plasma, 6.4 
±0.84 minutes (Ghosh et al. 2013). The codrug was able to keep the micropores 
open for seven days period, whereas with naltrexone gel under occlusion the 
pores were closed after 4 days. However this particular codrug was also 
chemically unstable (half-life of ca. 4 days in pH 5.0 buffer). Additionally the 
flux of naltrexone through the skin was evaluated to be lower than what 
would be required for clinically relevant plasma concentrations. Thus this 
particular prodrug was found not suitable for this kind of formulation. 
However, authors concluded that codrugs of NSAIDs combined with 
microneedle-treatment could be used to deliver naltrexone and other polar 
and high molecular weight compounds in transdermal sustained release 
formulation.  
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Figure 17. Structures of naltrexone (A), diclofenac (B) and the codrug of 
naltrexone and diclofenac (C) 
 
Codrugs are widely reviewed by Das et al. (2010). The major therapeutic areas 
where codrug strategy has been studied are CNS diseases such as Parkinson’s 
and Alzheimer’s diseases, oncology and inflammatory gastrointestinal 
diseases as well as antibiotics.   
 
 
8. ENZYMES INVOLVED IN PRODRUG ACTIVATION 
 
Enzymes involved in prodrug activation have not been as widely studied as 
the enzymes involved in drug metabolism, such as cytochrome P450 enzymes 
(CYPs). Understanding the enzyme responsible of the in vitro activation helps 
in the selection of preclinical species since much is known about the 
expression enzymes in different species and tissues. The enzymes known to 
contribute prodrug bioactivation are discussed here based on their substrates 
and their distribution.  
 
8.1. Carboxylesterases 
 
Carboxylesterases (CES) are hydrolytic enzymes located in endoplasmic 
reticulum (Hosokawa 2008). CESs are classified as serine proteases as they 
possess similar serine containing catalytic triad as e.g. chymotrypsin. They 
are divided into 5 families, two of which are mainly involved in prodrug 
bioactivation in human: CES1 and CES2. Both enzymes are expressed in 
32 
 
liver, whereas only CES2 is found in the small intestine (Taketani et al. 2007). 
Tissue distribution of CES isoenzymes in various animals is listed in Table 4. 
CES enzymes are also found in dog, rat, mouse and rabbit plasma, but not in 
the plasma of primates (Williams et al. 2011; Li et al. 2005). 
 
Table 4. Distribution of carboxylesterases and differences between species. 
CES1 is expressed in liver in all of the species in question. CES2 on the other 
hand is the main isoenzyme found in small intestine with the exception of 
guinea pig. +++ high expression, ++ moderate expression, + low expression, - 
undetectable, NT not tested.  (Taketani et al. 2007; Hosokawa 2008; Ishizuka 
et al. 2013)  
Species 
CES 
family 
Liver Small intestine Kidney Lung 
Human 
CES1 
CES2 
+++ 
+ 
- 
+++ 
+ 
+++ 
+++ 
- 
Rat (Sprague-Dawley) 
CES1 
CES2 
+++ 
- 
- 
+++ 
+++ 
- 
+++ 
- 
Dog (Beagle) 
CES1 
CES2 
+++ 
++ 
- 
- 
++ 
NT 
+++ 
+ 
Monkey (Cynomolgus) 
CES1 
CES2 
+++ 
+ 
++ 
+++ 
- 
+ 
+ 
NT 
Mouse 
CES1 
CES2 
+++ 
+++ 
- 
+++ 
+++ 
+++ 
+++ 
- 
Guinea pig 
CES1 
CES2 
+++ 
- 
+++ 
+ 
++ 
- 
NT 
NT 
 
CES enzymes have broad substrate specificity, which is speculated to be 
possible due to relatively large and flexible binding pocket, capable for 
numerous binding interactions (Liederer and Borchardt 2006). However, 
CES1 and CES2 families differ from each other in terms of substrate 
specificities (Hosokawa 2008). While CES1 isoenzymes seem to prefer 
hydrolyzing ester, amide and thioester bonds with small alcohol/amine/thiol 
moiety i.e. ester/amide/thiol promoieties attached into carboxylic group of 
drug moiety. Enzymes of the CES2 family however seem to prefer prodrugs 
esterified with small carboxyl function containing promoieties. Known 
prodrug substrates of CES include candesartan cilexetil and oseltamivir both 
of which are substrates to CES1 (Ishizyka et al. 2013; Hosokawa et al. 2008). 
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On the other hand mycophenolate mofetil, prodrug of an immunosuppressant 
agent, is hydrolyzed by both CES isoenzymes (Fujiyama et al. 2010).  
 
8.2. Paraoxonase 
 
There are three isoenzymes in the human paraoxonase (PON) enzyme family: 
PON1, 2 and 3 (Draganov and La Du 2004). Interpreting the literature 
considering PON can be problematic: These enzymes have multiple names 
(paraoxonase, arylesterase, aryldialkylphosphatase) named after the 
substrates of these enzymes and moreover PONs have two enzyme 
commission numbers (EC 3.1.8.1 and 3.1.1.2) (Liederer and Borchardt 2006). 
 
PON enzymes hydrolyze e.g. esters of aromatic carboxylic acid, 
organophosphates, lactones and cyclic carbonates (Liederer and Borchardt 
2006). These structures are present in known prodrug substrates of PONs, 
such as olmesartan medoxomil, prulifloxacin and statins such as simvastatin 
(Figure 7A and Figure 18). Paraoxonases require Ca2+-ion as cofactor and can 
be inhibited by chelating agents such as EDTA (Liederer and Borchardt 2006, 
Ishizuka et al. 2010). 
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Figure 18. Prodrugs substrates to paraoxonase: prulifloxacin (A) and 
simvastatin (B). Paraoxonase hydrolyses the cyclic carbonates and lactone 
ring found in the structures of these prodrugs. 
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Human PON1 and PON3 are mainly found in liver microsomal fraction and 
together with high-density lipoproteins in blood (Liederer and Borchardt 
2006). Whereas PON2 is distributed throughout the body, but not found in 
plasma (Draganov and La Du 2004). 
 
8.3. Butyrylcholinesterase 
 
Butyrylcholinesterases (BuChE) exist both in soluble and membrane-bound 
form and like carboxylesterases they are serine proteases (Dave at al. 2000). 
In both human and rat blood, cholinesterase is found in membrane-bound 
form in erythrocytes and in soluble form in plasma. BuChE is distributed to 
other tissues as well, including liver, brain and muscles. 
 
BuChE is able to hydrolyze ester and carbamate bonds. As discussed above 
bambuterol is hydrolyzed by BuChE (Tunek and Svensson 1988). 
Interindividual variation in BuChE activity was also observed in this study 
and rate of bambuterol hydrolysis correlated well with the measured BuChE 
activity. Interindividual variation is thus something to consider if targeting 
BuChE. 
 
8.4. Alkaline phosphatase  
 
Alkaline phosphatases (ALP) are found in various mammalian tissues 
especially liver, kidney, bone, placenta, intestine and plasma (Goldstein et al. 
1980; Moss 1982). The alkaline phosphatase isoenzymes found in liver bone 
and kidney are of same gene origin and resemble each other in terms of 
catalytic activity and antigenicity. All of these isoenzymes are also observed 
in plasma. In tissues ALPs are attached to plasma membranes with 
phospholipid anchor (Stinson and Hamilton 1994). Following removal of 
phospholipid anchor ALP is segregated to extracellular space in soluble dimer 
form, which is found in plasma. 
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Clear advantages of phosphate ester prodrugs are the ubiquitous ALP activity 
in preclinical species and human and the nontoxic promoiety (Rautio et al. 
2008). For most substrates the slowest and thus the rate limiting step in ALP 
mediated hydrolysis is the dephosphorylation of the enzyme (k3 in Equation 
5) (Heimbach et al. 2003b). Thus at high concentration, much higher than the 
Michaelis-Menten constant Km, the maximum rate of enzymatic activity does 
not depend on the substrate as k3 is independent of the prodrug. This means 
that the rate of promoiety hydrolysis does not vary greatly between prodrugs. 
 
 
     (5) 
 
 
8.5. Carboxymethylenebutenolidase 
 
Human carboxymethylenebutenolidase (CMBL, EC 3.1.1.45) has not been 
widely studied. Very little is known about the substrates of this enzyme and 
its function in eukaryotic cells (Ishizuka et al. 2010). However, it has been 
demonstrated that CMBL hydrolyzes olmesartan medoxomil and another 
angiotensin receptor antagonist prodrug azilsartan medoxomil (Ishizuka et 
al. 2010; 2013). The promoiety being a shared structure between these two 
prodrugs. Addition to these prodrugs no other reference of CMBL involvement 
in prodrug bioactivation can be found in literature, probably because the 
limited knowledge concerning CMBL. 
 
CMBL is a cytosolic protein found in intestine, liver and kidney of various 
species (Figure19) (Ishizuka et al. 2013). Clear exception is dog were CMBL 
was not detected in intestinal cytosols (Figure 19). Additionally weaker bands 
in the western plot analysis was observed microsomal fractions, but not in 
plasma. 
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Figure 19. Western-plot analysis of CMBL expression in subcellular fractions 
and plasma various species. CMBL is cytosolic protein found in liver, kidney 
and intestine. Exception to this was dog, where CMBL was not detected in 
intestinal cytosol. Applied amount of subcellular fraction in monkey and 
human is 4-fold compared to other species. Proteins were separated 
electrophoretically and stained using polyclonal anti-human CMBL 
antibodies. Theoretical mass of CMBL is 25kDa and highlighted with a 
marker. (From Ishizuka et al. 2013) 
 
8.6. Alpha-amino-acid esterase 
 
Alpha-amino-acid esterase is also known as valaciclovirase (EC 3.1.1.45) due 
to its ability to hydrolyze valaciclovir (Kim et al. 2003). The highest 
expression of alpha-amino-acid hydrolase in human is in the kidney and liver, 
but it is also expressed in the intestine (Lai et al. 2008). 
 
Like the name of the enzyme suggests, it hydrolyses efficiently various α-
amino acid esters with free α-amino group (Table 5). Of the current prodrugs 
valaciclovir and valganciclovir bioactivation is alpha-amino-acid esterase 
mediated (Lai et al. 2008). 
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Table 5. Hydrolytic activity of purified alpha-amino-acid esterase towards 
different amino acid esters. The enzyme is capable of hydrolyzing esters of 
most α-amino acids, the highest rate being with proline and alanine esters 
(Form Lai et al. 2008) 
Specificity towards the amino acid group 
Activity at 37°C  (µmol/min/mg of 
enzyme) 
Valacyclovir 103.7 ± 2.7 
L-Ala benzyl ester 1367.7 ± 94.3 
L-Gly benzyl ester 849.4 ± 25.1 
L-Pro benzyl ester 5148.4 ± 215.5 
L-Leu benzyl ester 635.0 ± 23.9 
L-Val benzyl ester 156.3 ± 7.4 
L-Met methyl ester 156.2± 12.3 
L-Phe benzyl ester 358.3 ± 34.8 
L-Tyr benzyl ester 41.4 ± 0.9 
L-Trp methyl ester 35.3 ± 2.0 
L-Ser benzyl ester 484.3 ± 30.0 
L-Asn p-nitrobenzyl ester – 
L-Asp benzyl ester – 
Specificity towards the leaving group 
Activity at 37°C  (µmol/min/mg of 
enzyme) 
L-Phe benzyl ester 358.3 ± 34.8 
L-Phe ethyl ester 75.3 ± 3.1 
L-Phe t-butyl ester – 
 
8.7. Aldehyde oxidase 
 
Aldehyde oxidases (AO) are an enzyme family of a cytosolic oxidizing enzymes 
(Garattini et al. 2008). Only one AO isoenzyme is found in human, whereas 
rodents have four isoenzymes. In canines however, the gene coding for human 
AO homolog is inactive. Highest expression of AO in human is in liver. AO 
activity has shown clear differences between species and even between sexes 
(Klecker at al. 2006). E.g. dog liver contains very low or no AO activity. In 
mouse the Vmax/km ratio in AO mediated zebularine oxidation was 13-fold 
higher in male than in female. However, this sex difference was not observed 
in human or rat. 
 
AO is able to oxidize aldehydes and heterocyclic compounds (Zientek et al. 
2010). As discussed above famciclovir and the deacetylated intermediate 
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metabolites are AO substrates and contain heterocyclic structures (Figure 
20). AO is additionally known to contribute for example zoniporide 
metabolism. 
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Figure 20. Structures of two known aldehyde oxidase substrates: penciclovir 
(A) and zoniporide (B). 
 
8.8 Cytochrome P450 
 
Cytochrome P450 enzymes (CYPs) are generally associated with the 
metabolism of drugs and other endogenous compounds. These enzymes have 
also been shown to contribute bioactivation of clopidogrel, a bioprecursor 
prodrug of antiplatelet aggregation agent (Dansette et al. 2009; 2013). More 
interestingly PON and CES enzymes discussed above as being bioactivating 
enzymes are the inactivating enzymes in the case of clopidogrel (Dansette et 
al. 2013; Qiu et al. 2013; Zhu et al 2013). The formation of intermediate 
thiolactone metabolite requires NADPH (a CYP cofactor), which strongly 
implies CYP mediated reaction. The structure of clopidogrel as well as 
proposed route of bioactivation and inactivation is presented in Figure 21.  
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Figure 21. Proposed route of clopidogrel bioactivation and metabolism. 
Clopidogrel (A) bioactivation requires NADPH indicating CYP mediated 
bioactivation. The second CYP mediated oxidation leads to formation of 
reactive thiolactone sulphoxide rapidly hydrolyzed to active metabolite (E). 
Demetylation of the carboxylic group is CES1 mediated leading to inactive 
metabolites (Dansette et al 2013; Qiu et al. 2013; Zhu et al. 2013). 
 
 
9. IN VITRO MATRICES TO STUDY PRODRUG METABOLISM 
 
For in vitro screening of prodrugs multiple matrices can be used to estimate 
the in vivo bioactivation of the prodrugs. Using the right matrices in in vitro 
screening is crucial in order to choose the right prodrugs for further in vivo 
studies. The problem addressed with the prodrug strategy defines which 
matrices are important to study. Possible prodrug approaches for different 
problems addressed and the selection of in vitro matrices are listed in 
Appendix I. The first key factor is to understand where the bioactivation 
should preferably occur and where it should not. E.g. if the objective is to 
reduce extensive first-pass metabolism the preferred site of activation would 
probably be in plasma or other non-metabolic tissue and definitely not in 
intestine or liver. 
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Centrifugation at 9000g 
Centrifugation at 
100000g (supernatant) 
Centrifugation at 100000g 
(resuspended pellet) 
 
Figure 22. Preparation of in vitro matrices. Tissue homogenates are prepared 
by grinding and mixing tissue samples. By centrifugation (9000g, ~20 
minutes) cell debris are separated and supernatant forms S9 fraction. 
Further centrifugation at 100000g for 60 minutes sediments microsomes and 
the supernatant (cytosolic fraction) can be removed. Microsomal fraction is 
obtained by resuspending the pellet formed in this latter centrifugation 
(Duffus et al. 2007). 
 
In vitro bioactivation can be studied in various matrices: Whole cells, tissue 
homogenates, S9 fractions (9000g supernatants), microsomes, cytosolic 
fractions or recombinant enzymes. The relation of these matrices is indicated 
in Figure 22. From Figure 22 it is evident that S9 fraction contains both 
cytosolic and microsomal fraction. Table 6 summarizes the distribution of the 
bioactivating enzymes in subcellular fractions and plasma as discussed 
above.   
 
Many of the enzymes contributing prodrug activation show clear differences 
between species thus it is important to conduct comparative in vitro studies 
in different species. This helps in the selection of the species for preclinical 
studies. The species that show similar rates of hydrolytic activity than human 
in vitro should be selected for preclinical studies. 
Tissue e.g. liver 
Whole cells 
Tissue homogenate 
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Table 6. Subcellular location of the enzymes known to contribute prodrug 
bioactivation. Enzymes present in either microsomal or cytosolic fraction are 
also present in S9 fractions. Of microsomal and cytosolic fractions, only the 
subcellular fraction containing the most of the enzyme is marked with +. 
Enzymes: Carboxylesterases (CES), paraoxonase (PON), Carboxymethylene-
butenolidase (CMBL), butyrylcholinesterase (BuChE), alkaline phosphatase 
(ALP), α-amino-acid esterase, aldehyde oxidase (AO), cytochrome P450 (CYP).  
Enzyme Microsomal Cytosol Plasma 
Tissue distribution 
in humans 
Considerations 
CES + - (+)* 
Liver (CES1,CES2) 
Intestine, Kidney 
(CES2) 
Lung (CES 1) 
*Only in dog and 
rodent plasma not 
human 
PON + - + 
Liver  
Plasma (PON1 and 
PON3) 
 
CMBL - + - 
Liver, intestine, 
kidney 
Not found in dog 
intestine 
BuChE - - + 
plasma, 
erythrocytes, liver, 
brain, muscles 
plasma membrane 
bound in various 
tissues  
ALP - - + 
liver, kidney, bone, 
placenta, intestine 
and plasma 
plasma membrane 
bound in various 
tissues 
α-amino-
acid 
hydrolase 
+ - - 
Kidney, liver, 
intestine 
 
AO - + - 
Mainly liver very little AO 
activity in dog liver 
CYP + - - 
Liver, intestine Also in other tissues 
but lesser amount 
 
9.1. Enzymatic activation in vitro 
 
If the prodrug is converted to APC in the metabolic tissue such as liver or 
intestine, it is also in interest to evaluate how APC formation compares to the 
formation of inactive metabolites of both prodrug and the APC (Imai and 
Hosokawa 2010). Figure 23 demonstrates three metabolic rates which have 
effect on APC plasma concentration via formation and elimination. Too slow 
formation of APC (k1) compared to excretion and eliminating metabolism of 
both prodrug (k2) and drug (k3) is likely to result low plasma concentrations 
of APC. If the site of prodrug activation is in metabolic tissue, the rates of 
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bioactivation should be compared to the rates of nonproductive prodrug 
metabolism and to the metabolic stability of the APC. If the latter two or 
either one of them is extensive compared to bioactivation, it is unlikely that 
the APC is formed sufficiently. Thus it is in interest to study how in vitro APC 
formation differs with and without the usual cofactors of metabolic enzymes. 
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Fig 23 Schematic model of prodrug bioactivation and elimination in vitro. k1 
is the rate of bioactivation as k2 and k3 represent the nonproductive 
metabolism of the prodrug and the APC. R = APC, R’ = promoiety and RM = 
metabolized APC (Modified from Imai and Hosokawa 2010). 
 
Using only in vitro data and in silico modelling Malmborg and Ploeger (2013) 
were able to achieve quite good correlation between simulated plasma 
concentrations and in vivo observations. Although e.g. Cmax of orally 
administered terbutaline was clearly overestimated in the in silico model, the 
study demonstrated that in vitro data such as hepatocytic CLint of APC, 
prodrug formation rates in S9 fractions and plasma and prodrug stability in 
GI fluids can be used to estimate in vivo plasma concentrations. 
 
 
10. PURPOSE OF THE STUDY 
 
The purpose of this study was to develop non-cell-based in vitro methods for 
screening the activation of diverse type of prodrugs using commercially 
available prodrug – parent drug combinations. Studies were performed using 
different biological matrices such as plasma and S9 cell fractions of intestine 
43 
 
and liver. Different combinations of biological matrices and enzyme cofactors 
were tested to find out optimal screening system for different types of 
prodrugs. 
 
The formation of APC as well as nonproductive metabolism of the prodrug 
was evaluated and discussed in comparison to the in vivo pharmacokinetics 
found in the literature. Several phenomena associated with these prodrugs 
were observed. The emphasis was on sequential mixed-type prodrugs (like 
famciclovir) and their metabolic activation in vitro. The effect of the promoiety 
on oral absorption was evaluated using parallel artificial membrane 
permeability assay (PAMPA). 
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Experimental part 
 
 
11. MATERIALS 
 
Prodrug compounds used in the studies were chosen to represent different 
chemical structures and so that the enzyme responsible for bioactivation 
would vary. An important criterion was also that both the APC and the 
prodrug were commercially available. Table 7 lists all the prodrugs and APCs 
used and their vendors. Structures are presented in Figure 24. All the 
prodrugs used in the study are discussed in the Literature Review above. In 
the case of famciclovir also the major intermediate metabolites leading to 
penciclovir were commercially available and purchased as reference 
standards for quantitative analysis. All the solvents used were of analytical 
grade (Acetonitrile, DMSO and formic acid). Purified water was used 
(Millipore).  
  
Table 7 prodrugs and APCs used in the study 
Prodrug Vendor Country 
Famciclovir Sigma-Aldrich Chemie GmbH Germany 
Desacetyl famciclovir Santa Cruz Biotechnology Inc. CA, USA 
6-deoxypenciclovir Santa Cruz Biotechnology Inc. CA, USA 
Penciclovir Sigma-Aldrich Chemie GmbH Germany 
Candesartan cilexetil Sigma-Aldrich Chemie GmbH Germany 
Candesartan Selleck Chemicals LLC TX, USA 
Olmesartan medoxomil Santa Cruz Biotechnology Inc. CA, USA 
Olmesartan Santa Cruz Biotechnology Inc. CA, USA 
Bambuterol Sigma-Aldrich Chemie GmbH Germany 
Terbutaline Sigma-Aldrich Chemie GmbH Germany 
 
The enzyme cofactors used in some of the incubations were purchased from 
Sigma-Aldrich (Germany). These included β-nicotinamide adenine 
dinucleotide phosphate (a cofactor of cytochrome P450, NADPH), uridine 5´-
diphospho-glucuronic acid (a cofactor for UDP-glucuronosyltransferase, 
UDPGA) and 3´-phosphoadenosine-5´-phosphosulfate (a cofactor for 
sulfotransferase, PAPS). 
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Figure 24. The structures of reference prodrugs and their APCs. Bambuterol 
(A) and its APC terbutaline (B); candesartan cilexetil (C) and APC, 
candesartan (D); olmesartan medoxomil (E) and APC olmesartan (F); 
famciclovir (G), the intermediate metabolites desacetyl famciclovir (H) and 6-
deoxypenciclovir (I) and the APC penciclovir (J).  
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Biological matrices used are listed in Table 8. Whole human blood was 
obtained from one healthy male volunteer (in house Orion Pharma). A total 
of 18 ml of blood was collected to 3 ml vacuum tubes containing EDTA. The 
blood was used at the day of collection and only slight amount of hemolysis 
was observed visually. 
 
Table 8. Matrices used in studies. Genders: F/M (female/male). The species 
used: R = rat, D = dog, H = human,  
Matrix Strain Gender (n) Supplier Country 
H plasma - Mix Sera Lab. International 
LTD 
UK 
R plasma Wistar F (155) Harlan Lab. Inc. USA 
D plasma Beagle Mix Harlan Lab. Inc. USA 
H duodenal 
S9 
- Mix 
(3M+3F) 
DB biosciences USA 
H jejunal S9 - Mix 
(6M+4F) 
DB biosciences USA 
H ijeunal S9 - F (10) DB biosciences USA 
R intestinal S9 Wistar M Orion Finland 
D intestinal S9 Beagle M (6) Xenotech USA 
H Liver S9 - Mix (20) DB biosciences USA 
R Liver S9 Spraque-
Dawley 
M (42) DB biosciences USA 
D liver S9 Beagle M (8) DB biosciences USA 
 
 
12. METHODS 
 
12.1. In vitro incubations 
 
In order to study rates of bioactivation the prodrugs were incubated in various 
matrices (Table 9). In general the incubation matrices consisted of the 
biological matrix studied (plasma, liver S9, intestine S9, whole blood or 
combination of two of these), the possible cofactor solutions prepared in 100 
mM phosphate buffer (pH 7.4) containing 5 mM of MgCl2, the pore forming 
peptide alamethicin (in incubation with S9 fractions) and the test compound 
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solution. Cofactors were used in some incubation to observe the effect of 
nonproductive metabolism on APC formation rate. The species studied were 
human, rat and dog. Of which rat and dog are rodent and non-rodent species 
commonly used in toxicology studies. 
 
Table 9. List of studies performed with reference prodrugs. OM = olmesartan 
medoxomil, CC = candesartan cilexetil, IS9 = intestinal S9 fraction, LS9 = 
liver S9 fraction. The species used R = rat, H = human and D = dog. Cofactors 
used: NADPH, UDPGA, and PAPS (+ = with and - = without) 
Prodrugs  
(C in µM) 
Species Matrices Cofactors 
(+/-) 
Time points 
(min) 
Limits of 
quantitation 
Bambuterol (1) R/H/D Plasma - 0,20,60,180, 120 0,01µM-2µM 
Bambuterol (1) 
 
R/H/D 
R/H/D 
R/H/D 
Plasma 
Plasma+IS9 
Plasma+LS9 
- 
- 
- 
0,20,60, (180) 0,01µM-2µM  
Bambuterol (1) H 
H 
H 
Whole blood 
plasma 
erythrocytes 
- 
- 
- 
0,20,60, 120 - 
Bambuterol 
(0,3/0,1/ 0,05) 
R/H/D Plasma - 0,10,20, 30,60, 
120,180, 240 
0,001µM-
0,5µM 
OM (1) R/H/D 
R/H/D 
R/H/D 
Plasma 
Plasma+IS9 
Plasma+LS9 
- 
- 
- 
0,20,60, (180) 0,01µM-2µM  
OM (1) 
 
R/H/D IS9 
LS9 
+ / - 
+ / - 
0,20,75, 150 0,01µM-1µM 
 
CC (1) R/H/D IS9 
LS9 
+ / - 
+ / - 
0,20,75, 150 0,005µM-
1µM 
CC (1) 
 
R/H/ 
D(LS9 only) 
LS9  
IS9 
LS9+IS9  
+ / - 
+ / - 
+ / - 
0,10,20, 40, 75 0,01µM-2µM 
 
 
Famciclovir (2) R/H/ 
D(LS9 only) 
LS9  
IS9 
LS9+IS9 
+ / - 
+ / - 
+ / - 
0,10,20, 40, 75 0,005µM-
2µM 
 
In combinational incubations the incubation matrix contained two different 
biological matrices in 1:1 ratio. Plasma and whole blood were used undiluted. 
The protein concentration was not determined, but in all species the plasma 
used in incubations was from same batch. S9 fractions were diluted with 
phosphate buffer so that the protein concentration in incubation solution was 
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0.9 mg/ml. Human intestinal S9 was pooled from pooled duodenal, jejunal and 
ileunal S9 fractions (Table 8).  
 
In order to distinguish chemical instability from enzymatic activation, the 
chemical instability was measured in 100 mM phosphate buffer (pH 7.4) with 
5mM of MgCl2 in all incubations. The test compound stock solutions (1mM) 
were prepared in DMSO and further diluted to 100 times the incubation 
concentration with DMSO. The total DMSO concentration in incubations was 
1%. 
 
Incubations were performed in 96-well plate, which was placed on 
Thermomixer (Eppendorf, Germany) at 37°C and mixing 750 rpm. The whole 
blood incubation was conducted with lower mixing speeds (300 rpm) because 
of the fragile nature of erythrocytes. The incubations were initiated by adding 
the test compound solution into prewarmed incubation matrix with final test 
compound concentration being 0.05-2 µM (Table 9). Prewarming was 
conducted in Thermomixer for 10-15 minutes. At specific time points (0-240 
min, Table 9) aliquots of incubation solutions were removed into cold 
acetonitrile and mixed twice with pipet to precipitate proteins and so to 
terminate enzymatic reactions. The sample plates were placed to -80°C until 
further sample preparations and analysis. The acetonitrile to sample aliquots 
ratio varied between the incubations depending on the matrix used, but was 
≥ 2 in all of the incubations and 4:1 in incubations containing plasma. 
 
Whole blood contains higher activity of some enzymes and enzymes (like CES) 
thet are not present in plasma (Fujiyama et al. 2010; Naik et al. 2012). Thus 
bambuterol was also incubated in whole human blood and erythrocytes. Two 
thirds of the blood collected was centrifuged (3000g, 7 minutes (Allegra X-12R 
-centrifuge, Beckman Coulter)) to separate plasma from erythrocytes. 
Erythrocytes were washed twice with equal volume of phosphate buffer saline 
pH 7.4 (PBS): Buffer was added, mixed gently with erythrocytes, centrifuged 
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(3000 rpm, 7 minutes) and the supernatant was removed. The color of the 
plasma suggested small amounts of hemolysis which was not observed with 
washed erythrocytes. Wider pipet tips were used to minimize hemolysis 
during pipetting of the blood. Sampling times were 0, 60 and 120 minutes. 
 
Prior to the analysis samples were thawed at room temperature, mixed in 
Thermomixer for 3 minutes and centrifuged at 3000 rpm for 7 minutes. The 
supernatant was transferred to a 96-well plate and injected into LC-MS/MS. 
LC-MS/MS analyses are described in 12.2. 
 
In addition to the actual studies the effect of mixing on precision was 
validated in a pre-study. The best precision was obtained when incubation 
solutions were mixed for 20-30 seconds in the Thermomixer prior to removing 
of the 0-minute sample and the incubation solution was mixed twice with 
pipette before removing the aliquots (data not shown).  
 
12.2. LC-MS/MS methods 
 
LC-MS/MS methods were developed for all the analytes quantitated. The 
liquid chromatograph used was Acquity UPLC system (Waters, USA) 
consisting of binary solvent manager, sample manager and column. The 
columns used were reverse phase columns (Acquity UPLC™ BEH Shield RP18 
1.7µm, 2.1 x 100 mm and Acquity UPLC™ BEH C18 1.7µm, 2.1 x 100 mm 
(Waters, USA)). The column used for each analyte is listed in Appendix II. 
The temperature of sample manager was 10°C and 55°C for column, 
respectively. The mobile phase used consisted of 0.1% formic acid in Millipore 
water and of acetonitrile. Gradient methods were used for each analyte 
(Appendix II) 
  
The mass spectrometer used was a triple quadrupole API 4000 (AB Sciex 
Instruments, USA) with TurboIonSpray interface. Positive electrospray 
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ionization (ESI+) was used as ionization technique for all the analytes. All 
analyses were performed using multiple reaction monitoring (MRM). More 
detailed information about the MS/MS methods used for each analyte is found 
in Appendix II and limits of quantitation are listed in Table 9.  
 
External standard curves were used in the quantitation (linear regression 1/x 
weighting for all analytes). The calibration curve samples and quality control 
(QC) samples were prepared by diluting the analytes quantitated with the 
incubation matrix and further diluting with equal volume of acetonitrile than 
what was used to terminate the incubation. I.e. standard and QC-samples 
were prepared in the same way as actual samples, but in room temperature 
not in 37°C. No dilution factors for standard curves were needed. For each 
incubation and incubation matrix a separate standard curve was used. 
Standard and QC-samples were prepared from different stock solutions. 
 
12.3. Calculations 
 
The rates of prodrug disappearance and APC formation, respectively were 
calculated using equation (6) and (7).  
Δ𝐶𝑃𝑟𝑜𝑑𝑟𝑢𝑔 𝑥 𝑉
Δ𝑡 
         (6) 
And 
Δ𝐶𝐴𝑃𝐶  𝑥 𝑉
Δ𝑡 
          (7) 
 
, where V is the volume of incubation matrix. In many of the incubation the 
loss of prodrug between the first time points was greater than 30%, meaning 
that sink conditions were not maintained. Thus the results of these 
calculations should be considered tentative.  
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12.4. Parallel artificial membrane permeability assay 
 
The effect of promoiety on absorption was estimated by determining the 
passive permeability of prodrugs and APCs in parallel artificial membrane 
permeability assay (PAMPA).  
 
PAMPA was performed on Stirwell™ PAMPA 96 well sandwich (Pion-Inc, 
USA). 10mM stock solutions of the test compounds were prepared in DMSO 
from freshly opened ampules DMSO Hybri-Max (Sigma-Aldrich, Germany). 
Stock solutions were diluted using Prisma HT –universal buffer (Pion-inc, 
USA) (pH 5.0 and pH 7.4) to 50 µM. The DMSO concentration in the test 
solutions was 0.5%. The absorbance of pH 5.0 and pH 7.4 buffers was 
measured at 210-500 nm (blank, background absorbance) at every 4 nm.  The 
absorbance of Prisma HT –buffer diluted stock solutions were measured the 
same way (reference). The spectrophotometer used was SpectraMax 190 
absorbance microplate reader (Molecular devices, LLC, USA)  
 
GIT-0 lipid solution (5 µl) (Pion-Inc, USA), simulating the lipid layer of the 
gastrointestinal tract, was inserted onto filters of the PAMPA sandwich. 200 
µl of the 50 µM test compound solutions were pipetted to donor side of the 
PAMPA sandwich and 200 µl of Double sink™ Acceptor Sink Buffer (ASB, 
Pion-Inc, USA) was placed to acceptor side of the PAMPA sandwich. The ASB 
contains surfactants to help solubility of lipophilic molecules into the acceptor 
side buffer and to reduce membrane retention of the molecules (Avdeef 2003).  
 
The PAMPA sandwich was then placed into Gut-Box™ (Pion-Inc, USA) at 
25°C without mixing. After four hours, aliquots were transferred from the 
acceptor side into a UV-plate and the absorbance at 210-500 nm was 
measured. Then the UV-plate was washed with 70% MeOH. Aliquots from 
donor side were transferred into the UV-plate and the absorbance was 
measured as described above. 
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In the case of bambuterol, terbutaline, famciclovir and penciclovir three 
parallel samples were prepared. Respectively, for olmesartan medoxomil, 
olmesartan, candesartan cilexetil and candesartan six parallel samples were 
used. Additionally one in-house synthetized molecule was used as a positive 
control. The apparent permeability was calculated using PAMPA Explorer 
Command Software (Pion-Inc, USA). The limits for permeability (Pe) of the 
positive control were 40-85 (10-6 cm/s) at pH 5.0 and 1.5-3.5 (10-6 cm/s) at pH 
7.4. Additionally the standard deviation of –logPe should be less than 0.2. 
 
 
13. RESULTS 
 
13.1 LC-MS/MS 
 
In general the LC-methods produced good separation of prodrugs and APCs. 
Figures 25-28 present typical MRM chromatograms obtained with the 
methods used. The intermediate metabolites of famciclovir (desacetyl 
famciclovir and 6-deoxypenciclovir) did not separate completely from 
penciclovir (Figure 27). However these compounds have completely different 
mass and were thus separated in MS/MS spectrum.  
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Figure 25. LC-MS/MS MRM chromatogram of bambuterol and terbutaline. 
The green peak at ca. 0.6 minutes represents terbutaline (MRM transition 
226152) and red and blue peaks are bambuterol. Blue peak was used in 
bambuterol quantitation (MRM transition 368312). 
 
 
Figure 26. LC-MS/MS MRM chromatogram of candesartan cilexetil (CC) and 
candesartan. Retention time for candesartan (green peak, MRM transition 
441263) was 1.9 min and for CC 2.4 min. The red peak (MRM transition 
612423) was used in CC quantitation. 
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Figure 27. LC-MS/MS MRM chromatograms of APC penciclovir (A), prodrug 
famciclovir (B) and intermediate metabolites desacetyl famciclovir (C) and 6-
deoxypenciclovir (D). 
 
The tailing seen in the peak of desacetyl famciclovir (Figure 27, C) was 
observed in all of the samples analyzed, even when desacetyl famciclovir 
dissolved in running solution was injected to LC-MS/MS system (data not 
shown). Desacetyl famciclovir is a chiral compound. Consequently it is 
possible that these peaks represent R- and S-enantiomers of desacetyl 
famciclovir. 
 
C) 
B) 
A) 
D) 
55 
 
 
Figure 28. LC-MS/MS MRM chromatogram of olmesartan medoxomil and 
olmesartan. Olmesartan (green peak, MRM transition 447207) eluted at 1.1 
minute and OM at ca. 2.5 minutes. Blue peak (MRM transition 559429) was 
used in the quantitation of OM. 
 
13.2 Incubations 
 
13.2.1 Bambuterol  
 
In plasma incubation with 1 µM incubation concentration of bambuterol, no 
terbutaline formation was observed (Figure 29). Moreover no considerable 
decrease in bambuterol concentrations were not observed in plasma of any of 
the species. 
 
Bambuterol (1µM) was incubated in combinatorial matrices of plasma with 
either liver (LS9) or intestinal (IS9) S9 fraction (Table 9). In rat and dog IS9 
with plasma and dog LS9 with plasma bambuterol concentrations decreased 
in higher rate at the beginning. Terbutaline was not formed during the 60 
minutes incubation (Figure 30).  
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Figure 29. Bambuterol stability in human, rat and dog plasma (bambuterol: 
prodrug, terbutaline: APC). No terbutaline formation was observed in 20 hour 
incubation. The incubation concentration was targeted to be 1 µM. Data 
presented as mean ± min-max values of two parallel incubations. 
 
 
Figure 30. Bambuterol incubated in combinatorial matrices: intestinal S9 
with plasma (dashed lines) and liver S9 with plasma (solid lines) (bambuterol: 
prodrug, terbutaline: APC). No terbutaline above the limit of quantitation 
was formed in any of the incubation matrices. Data presented as mean of 
duplicate incubations +/- min/max. 
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As previously reported by Tunek et al. (1988) the rate of terbutaline formation 
from bambuterol is dependent on bambuterol concentrations in vitro. The 
effect of concentration was studied by incubating bambuterol in rat, dog and 
human plasma in three different concentrations (Table 9). Concentrations 
used were lower than in previous incubations: 0.05 µM, 0.1 µM and 0.3 µM.  
 
Figure 31. Bambuterol incubated at different concentrations in human 
plasma. Initial concentrations of bambuterol (solid lines) were 0.05 µM (red), 
0.1 µM (green) and 0.3 µM (blue). The terbutaline (dashed line) formation 
increased when incubation concentration was decreased. The concentrations 
are expressed as % of the initial prodrug concentration. Data expressed as 
mean of duplicate incubations ± min-max. 
 
In this study terbutaline formation in vitro was achieved only in human 
plasma in incubation concentration 0.05-0.3 µM of the prodrug bambuterol 
(Figure 31 and Table 10). In human plasma the rate of terbutaline formation 
was highest at 0.05 µM incubation concentration and the rate degreased as 
incubation concentration was increased (Table 10). In 0.3 µM and 0.1 µM 
incubation concentration in human plasma also a biphasic elimination (rapid 
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initial phase, followed by slower 2nd phase) of bambuterol was observed which 
is proposed to be result of BuChE inhibition (Tunek and Svensson 1988) 
(Figure 31).  In rat or dog plasma no terbutaline was measured in any of the 
concentrations and bambuterol seemed stable (Figure 32). The data obtained 
from this study is consistent of the studies performed by Tunek et al. (1988). 
Table 10 summarizes the incubations performed for bambuterol. 
 
 
Figure 32. Bambuterol in dog and rat plasma (incubation concentration 0.05 
µM). Terbutaline was not formed, not even in low incubation concentrations. 
Data expressed as mean of duplicate incubations ± min-max. 
 
Whole blood and erythrocyte incubations did not suit well for 96-plate format. 
The results were inconsistent. Due to high viscosity of these matrices, 
accurate pipetting of small volumes proved to be problematic. Even though 
reverse pipetting was used, the desired accuracy was not achieved. The 
addition of ACN made the blood clot resulting ununiformed samples. 
Therefore these samples could not be analyzed reliable. 
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Table 10: Rates of bambuterol disappearance and terbutaline formation in 
different matrices in vitro. 
Prodrug (C: 
µM) 
cofactors matrix Species 
Rate of prodrug 
disappearance 
(pmol/min)* 
Rate of APC 
formation 
(pmol/min)* 
Bambuterol 
(1) 
- Plasma Rat 2.0 < 
-  Human 6.8 < 
-  Dog 12.4 < 
- IS9+P Rat 12,9 < 
-  Human 3,6 < 
-  Dog 9,7 < 
- LS9+P Rat 3,0 < 
-  Human 1,6 < 
-  Dog 6,8 < 
Bambuterol 
(0,05) 
- Plasma Rat < < 
-  Human 2.2 0.06 
-  Dog NA < 
Bambuterol 
(0,1) 
-  Rat < < 
-  Human 2.6 0.03 
-  Dog < < 
Bambuterol 
(0,3) 
-  Rat < < 
-  Human 1.5 0.01 
-  Dog < < 
* No sink conditions, results are tentative   
 
13.2.2 Olmesartan medoxomil  
 
Olmesartan medoxomil (OM) was studied in plasma, in IS9 and LS9 with and 
without cofactors and additionally in combinatorial matrices of IS9 or LS9 
with plasma (Table 9). At first the incubation was performed without 
cofactors. OM was very unstable in plasma alone as well as in the 
combinatorial matrices (plasma with IS or LS9) (Figure 33 Table 11).  
 
Additionally, OM was incubated with cofactors in intestinal and liver S9 
fraction. In dog and rat intestinal S9 fraction the formation of free olmesartan 
was slower than in other of matrices studied (Figure 34 and Table 9). In 
human intestinal S9 fraction OM was rapidly hydrolyzed and no OM was 
detected at first time point. However, the measured concentrations of 
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olmesartan were lower than the initial concentration of OM even though the 
olmesartan concentrations seemed to reach a plateau. This is further 
discussed later. Similarly the rates of OM hydrolysis and olmesartan 
formation were high in liver S9 fraction of rat, dog and human as well. 
 
 
Figure 33. Olmesartan medoxomil in plasma and formation of olmesartan in 
combinatorial matrices). OM hydrolysis was observed in plasma of rat, 
human and dog. (Olmesartan medoxomil (OM): prodrug, olmesartan (Olm): 
APC). Data presented as average of two parallel incubations ± min-max 
 
The hydrolytic activity was lower in rat and dog IS9 fraction compared to 
other matrices studied. In the study by Ishizuka et al. (2013), rat intestinal 
microsomes showed low hydrolytic activity, which was not observed at all in 
cytosolic fraction of rat intestine or in microsomal or cytosolic fractions of dog 
(Figure 8). Interestingly, in this study dog IS9 fraction showed some 
hydrolytic activity when compared to buffer (Figure 34).  
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Figure 34. OM hydrolysis and olmesartan formation in buffer and in rat, dog 
and human S9 matrices with cofactors (WC) and without cofactors (NC). 
Cofactors used: NADPH, UDPGA and PAPS. The solid lines represent OM 
and the dashed lines free olmesartan, respectively. (OM: prodrug, 
olmesartan: APC) Data expressed as mean of duplicate incubations. 
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As seen in Table 11 and Figure 34 the rate of OM disappearance and APC 
formation was higher in human intestinal S9 fraction compared to 
corresponding rat and dog S9 fractions. Otherwise no clear species differences 
were not observed. The rapid rates of hydrolysis of OM is consistent with the 
in vivo data (Laeis et al. 2001) as no intact prodrug is observed in vivo. 
 
Table 11. Rates of olmesartan formation and olmesartan medoxomil 
disappearance in different incubation matrices with and without cofactors. 
Prodrug 
(C: µM) 
cofactors matrix Species 
Rate of prodrug 
disappearance 
(pmol/min) ** 
Rate of APC 
formation 
(pmol/min) ** 
Olmesarta
n 
medoxomil 
(1) 
- IS9+P Rat* 3,0 8,1 
- IS9+P Human 11,3 9,6 
- IS9+P Dog 9,3 9,0 
- LS9+P Rat 18,0 9,7 
- LS9+P Human 16,4 8,6 
- LS9+P Dog 17,6 11,0 
PAPS, 
NADPH, 
UDPGA 
IS9 Rat 3,2 2,1 
PAPS, 
NADPH, 
UDPGA 
IS9 Human NA*** NA*** 
PAPS, 
NADPH, 
UDPGA 
IS9 Dog 2,3 1,7 
PAPS, 
NADPH, 
UDPGA 
LS9 Rat NA*** NA*** 
PAPS, 
NADPH, 
UDPGA 
LS9 Human NA*** NA*** 
PAPS, 
NADPH, 
UDPGA 
LS9 Dog NA*** NA*** 
- IS9 Rat 4,9 4,7 
- IS9 Human NA*** NA*** 
- IS9 Dog 5,5 5,4 
- LS9 Rat NA*** NA*** 
- LS9 Human NA*** NA*** 
- LS9 Dog NA*** NA*** 
* Rate of prodrug disapperance  underestimated because the C0 was already very low 
** No sink conditions, results are tentative, *** Rate too high to calculate  
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13.2.3 Candesartan cilexetil 
 
Candesartan cilexetil (CC) was incubated in IS9 and in LS9 with and without 
cofactors (Table 9). The cofactors used were NADPH, PAPS and UDPGA. The 
sampling times were 0, 20, 40 and 75 minutes. Additionally CC was incubated 
in rat and human IS9, LS9 and in combination matrix consisting of both IS9 
and LS9 in 1:1 ratio, and in dog LS9.  
 
 
Figure 35. Formation of candesartan from candesartan cilexetil (CC) in 
intestinal S9 fraction of rat, dog and human (CC: prodrug, candesartan: APC). 
The rate of CC hydrolysis was faster in rat and human S9 fractions compared 
to the respective dog S9 fractions. Data expressed as mean of duplicate 
incubations. 
 
The rate of candesartan formation in rat and human IS9 could not be 
calculated reliably from the data as almost all (if not all) of the prodrug was 
hydrolyzed into candesartan at the first time point. The hydrolysis of CC was 
very rapid in rat and human IS9 (Figure 35). Already at t0 ca. 20% of the 
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initial CC concentration was hydrolyzed to candesartan in rat IS9 indicating 
that during the ~20 second mixing after addition of the test compound 
considerable hydrolysis had occurred. The incubation of all three species were 
initiated and the aliquots were removed simultaneously using 8-channel 
pipette. Thus chemical instability would be expected to be similar in all 
matrices despite of the species. Additionally, no candesartan was formed 
during 75 minutes incubation in buffer solution at 37°C (Figure 36). 
 
CC hydrolysis was rapid in the first incubation and was thus incubated again 
in IS and LS9 matrices with the first time point being 10 minutes (instead of 
20 minutes) (Table 9). More specific the matrices used were rat and human 
IS9, LS9 and combination matrix of IS9 and LS9 and dog LS9. Comparison 
was made between incubations with and without cofactors (NADPH and 
UDPGA). Results of this incubation are presented in Figure 36. 
 
The rate of CC hydrolysis and candesartan formation was again high in all of 
the matrices studied, whereas no CC hydrolysis or candesartan formation 
was observed in buffer (Figure 36). In the incubations containing liver S9 
fraction with cofactors the candesartan concentrations started to decrease 
after 20 minutes of incubation, possible indicating nonproductive metabolism. 
In every biological matrix studied considerable amount of bioactivation was 
observed in t0 samples which was not observed in buffer suggesting enzymatic 
hydrolysis rather than chemical in stability (Figure 36). 
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Figure 36. Incubation of CC in LS9/ IS9 and IS9+LS9 of rat and human and 
in liver S9 fraction of dog (CC: prodrug, candesartan: APC). The results are 
presented as a percentage of the initial incubation concentration and as mean 
of duplicate incubations ± min-max. 
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13.2.4 Famciclovir  
 
Famciclovir was incubated in rat and human IS9, LS9. Additionally as 
deacetylation steps of famciclovir were reported to be site specific (first 
occurring preferably in the intestine and second in the liver (Vera Hodge et 
al. 1993)) the incubation was performed in combination matrices of IS9 and 
LS9 fractions (of rat and human). Comparison was made between incubations 
with and without cofactors (NADPH and UDPGA). 
 
In human the deacetylation of famciclovir was of high rate in all three 
matrices studied (Figure 37). Moreover the rate of the second deacetylation 
was lower. During the 75 minute incubation small amount of penciclovir was 
formed in matrices containing LS9 fraction. The rates of penciclovir formation 
were 0.4 pmol/min and 0.2 pmol/min in LS9 fraction and LS9+IS9 fraction, 
respectively (Table 12).  
 
The oxidation step of famciclovir bioactivation to penciclovir is mediated by 
aldehyde oxidase (EC 1.2.3.1) (Clarke et al. 1995). Considering that aldehyde 
oxidase is mostly expressed in cytosolic fractions of hepatocytes and lower 
expression levels are found in intestine (Garattini et al. 2008), these results 
are consistent with the literature. 
 
In rat intestinal S9 fraction formation of desacetyl famciclovir was of much 
lower rate than in corresponding human fraction and in line with the decrease 
in famciclovir concentrations (Figure 38). The concentrations of 6-
deoxypenciclovir where very low (ca. 0.5% of the initial concentrations) and 
no penciclovir was observed in rat IS9 fraction.  
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Figure 37. Famciclovir in human S9 fraction with and without cofactors. Mix 
S9 consisted of IS9 and LS9 in 1:1 ratio. The disappearance of famciclovir was 
relatively fast and the formation of desacetyl famciclovir correlated with it. 
The rate of desacetyl famciclovir hydrolysis to form 6-deoxypenciclovir was 
slower. Penciclovir formation was observed only in presence of LS9 
(famciclovir: prodrug, penciclovir: APC). Famciclovir was stable in buffer 
(data not shown) Data expressed as mean of duplicate incubations±min-max 
and as percentage of the initial concentration. 
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Figure 38. Famciclovir in rat S9 fractions with and without cofactors. Mix S9 
consisted of IS9 and LS9 in 1:1 ratio. Deasetyltion was slow in intestinal S9 
fraction and possibly also in liver S9 fraction. Since the concentrations of 
desacetyl famciclovir remain low in LS9 the decrease in famciclovir 
concentaration was possible due to oxidation of the heterocyclic ring leading 
to bis-acetylated penciclovir. The oxidation step occured only in incubations 
containing liver S9 fraction. Data expressed as mean of duplicate incubations 
and as percentage of the initial concentration. 
 
In liver S9 fraction of rat the concentrations of famciclovir decreased as fast 
as in human liver S9 fraction (Figure 38). However the concentrations of 
desacetyl famciclovir and 6-deoxypenciclovir remained very low. As discussed 
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above the steps of bioactivation are able to occur also in different order than 
what is represented in Figure 6. In this study the levels of di- and 
monoacetylpenciclovir were not quantitated. Based on literature (Vera Hodge 
et al. 1989) and present study, it is likely that in rat liver S9 fraction the route 
of activation is different than in human liver S9 fraction. The formation of 
penciclovir was higher in rat liver S9 fraction than in corresponding human 
fraction. At 75 minutes time point the concentrations of penciclovir were 7-
8% and 4-5% of the initial concentration in rat and human LS9, respectively. 
 
Additionally famciclovir was incubated in dog liver S9 fraction (Figure 39). 
Deacetylation of famciclovir was fast and comparable to human LS9 fraction. 
However the second acetylation was not as high rate in rat as in human LS9 
fraction (Figures 37 and 39). Moreover no penciclovir was formed during the 
incubation. This can be explained by the absence of aldehyde oxidase (AO) in 
canine liver (Garattini et al. 2008; Klecker et al. 2005).  
 
 
Figure 39. Famciclovir in dog liver S9 fraction. Fast deacetylation of 
famciclovir, but much slower deacetylation of desacetyl famciclovir was 
observed. Penciclovir was not observed (lack of oxidizing activity). Data 
expressed as mean of duplicate incubations and as percentage of the initial 
concentration. 
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Table 12. The rates of famciclovir disappearance and penciclovir formation in 
vitro. The data is expressed as mean of duplicate concentrations. The rates of 
famciclovir disappearance should be considered as tentative as no sink 
conditions were maintained.  
Prodrug  
(C: µM) 
cofactors matrix Species 
Rate of prodrug 
disappearance 
(pmol/min) 
Rate of APC 
formation 
(pmol/min) 
Famciclovir 
(2) 
- IS9 Rat 7,8 0,05 
- IS9 Human 68,5 < 
NADPH, 
UDPGA 
IS9 Rat 7,8 0,02 
NADPH, 
UDPGA 
IS9 Human 57,6 < 
- LS9 Rat 56,9 0,8 
- LS9 Human 44,4 0,8 
- LS9 Dog 25,2 < 
NADPH, 
UDPGA 
LS9 Rat 39,3 0,8 
NADPH, 
UDPGA 
LS9 Human 25,7 0,4 
NADPH, 
UDPGA 
LS9 Dog 17,0 < 
- IS9+LS9 Rat 36,8 0,3 
- IS9+LS9 Human 60,4 0,3 
NADPH, 
UDPGA 
IS9+LS9 Rat 26,0 0,3 
NADPH, 
UDPGA 
IS9+LS9 Human 38,5 0,2 
 
 
13.3 The effect of promoiety on passive permeability  
 
The permeability data of bambuterol, famciclovir, candesartan cilexetil and 
olmesartan medoxomil and the corresponding APCs obtained with PAMPA 
method are presented in Table 13. Of the prodrugs studied famciclovir OM 
and CC were developed to increase absorption after oral administration.  
 
Bambuterol had higher permeability at pH 7.4 than terbutaline, where the 
Papp increased from 0 to 15.8 10-6cm/s, but both compounds were poorly 
permeable at pH 5.0. Although the prodrug strategy was introduced to 
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terbutaline in order to reduce first pass metabolism, it seems that the 
promoieties of bambuterol additionally increase passive permeability. 
 
Famciclovir possessed slightly greater permeability compared to penciclovir, 
although the Peff of famciclovir was still low to moderate: 1 and 0.6 10-6cm/s 
at pH 5.0 and 7.4, respectively. 
 
In the case of candesartan, the prodrug (candesartan cilexetil) was more 
permeable in pH 7.4, whereas the APC itself seemed to possess high 
permeability in pH 5.0. The goodness-of-fit in regression analysis for 
candesartan cilexetil was only moderate (3), which might indicate instability 
of CC in transport medium. The promoiety of olmesartan medoxomil 
significantly increased the apparent permeability of olmesartan. At pH 5.0 
the apparent permeability increased from 0.4 to 36 10-6cm/s and at pH 7.0 
from 0.2 to 2.2 10-6cm/s. 
 
Table 13 Permeability of the studied prodrugs and their APCs in PAMPA. 
Values on red background are of low permeability (<1.0 x 10-6 cm/s), on yellow 
background moderate permeability (1.0-1.5 x 10-6 cm/s) and on green 
background good permeability (>1.5 x 10-6 cm/s). Data is presented as mean 
± standard deviation. The prodrugs are underlined. 
Compound 
Papp at pH 5,0 
(10-6 cm/s) 
Papp at pH 7,4 
(10-6 cm/s) 
Limits 
Goodness 
of fit  (1-5) 
Bambuterol 0.0 15.8±10.4 - 5 
Terbutaline 0.0 0.0 - 5 
Famciclovir 1.0±0.2 0.6±0.02 - 5 
Penciclovir 0.0 0.1±0.1 - 4 
Candesartan cilexetil 0.5±0.4 12.7±3.7 - 3 
Candesartan 27.5±5.9 0.5±0.4 - 4 
Olmesartan 
medoxomil 
36.4±9.9 2.2±0.2 - 5 
Olmesartan 0.4±0.3 0.2±0.1 - 4 
Control 69±24 1.9±0.6 40-85, 1.5-3-5 - 
Control (–logPe St 
dev) 
0.18 0.15 <0,2 - 
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14. DISCUSSION 
 
In vitro bioactivation of the studied prodrugs was achieved with the S9 
fraction based method used in this study. With the prodrugs studied no 
remarkable nonproductive metabolism could not be observed as no metabolite 
screening was performed. Moreover, the rates of APC formation varied 
greatly between the prodrugs studied.  
 
14.1 Analytical methods  
 
Quantitative analysis of prodrugs was challenging since some of the prodrugs 
were not stable enough in the solutions used. E.g. in the standard curve 
samples of olmesartan medoxomil a small peak for free olmesartan was 
observed in the MS/MS-spectrum, indicating that OM had partly hydrolyzed 
to olmesartan during sample storage or sample preparation. Similar problem 
was observed with candesartan cilexetil, but not with bambuterol or 
famciclovir. As seen in Figures 33-36 OM and CC were hydrolyzed at t0 in 
some of the matrices, but not in buffer. This rapid bioactivation possibly 
reduced the accuracy of the quantitation. Standard and quality control (QC) 
samples were prepared in the same way than the actual samples in order to 
minimize the effect of hydrolysis during sample preparation on quantitative 
accuracy. The sensitivities of the analytical methods were adequate.  
 
The quantitated concentrations of olmesartan were lower than the original 
OM concentration (Figures 33 and 34). However e.g. in plasma (Figure 33) 
olmesartan concentrations seemed to reach a plateau and no OM was 
observed after first two time points. Moreover with 0.75µM QC-samples of 
olmesartan similar inaccuracy (66 % of the nominal concentration) was 
observed whereas QC-samples of 0.3µM and 0.1µM were accurate (on average 
99.2% and 103.6% of the nominal concentration respectively). Olmesartan is 
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only slightly soluble in water (product information sheet). Because of the low 
solubility the quantitation above ca. 0.6µM cannot be considered reliable. 
 
In some incubations the sum of the concentrations of penciclovir, 6-
deoxypenciclovir, desacetyl famciclovir and famciclovir far exceeded the 
original incubation concentration at some time points. Especially the 
concentrations of desacetyl famciclovir were high in the presence of cofactors. 
The presence of cofactors may have altered the ionization of desacetyl 
famciclovir in samples, which could explain these abnormalities.  
 
In PAMPA permeability study the regression analysis produced goof fit with 
the exception of candesartan cilexetil which produced poor fit in pH 5.0. Most 
likely this was due to the poor solubility or instability of CC in the acidic 
aqueous media. However, based on literature candesartan should have even 
lower solubility than the prodrug (Darwhekar et al. 2012). The regression 
analysis of candesartan permeability produced good fit, which does not 
support the theory of these problems being due solubility limitations. The 
method was working properly for the positive control used in the study as it 
had permeability within the predefined limits (Table 13).  
 
14.2 In vitro bioactivation of the prodrugs 
 
Incubations with bambuterol demonstrated that especially when designing 
double or triple prodrugs the in vitro formation of APC can be concentration 
dependent. Observations of current study are consistent with the previously 
conducted studies and similar phenomenon is possible e.g. for various 
carbamate prodrugs (Tunek et al 1988). In vivo the concentrations of drugs 
are often quite low and more enzymes are present. Thus it is unlikely that 
concentrations of prodrug or intermediate metabolites would prevent APC 
formation in vivo. However bambuterol has shown saturable first-pass 
bioactivation (Rosenborg et al. 2000). This is something to be considered when 
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evaluating whether the rates of APC formation are sufficient to achieve 
therapeutically relevant concentrations. When prodrug strategy is used to 
reduce first-pass metabolism, saturable bioactivation could even have 
positive impact on oral bioavailability. Additionally biphasic in vitro 
hydrolysis of a prodrug might be an indication of autoinhibitory mechanisms, 
like in the case of bambuterol. 
 
The incubation of bambuterol in whole blood produced inconsistent results. If 
whole blood incubations are considered the method should be developed 
further. The pipetting of blood should be minimized in the study protocol. 
Additionally bigger volumes could produce more precise results. Sample 
preparation methods should be developed in order to produce more 
representative samples. Also it is important to choose right anticoagulant as 
e.g. EDTA is likely to inhibit calcium dependent enzymes such as 
arylesterase. 
 
OM is known to have relatively low bioavailability, ca. 30% (laeis et al. 2001). 
Moreover, in mass balance studies with 14C-labeled OM, olmesartan was the 
only source of radioactivity recovered from fecal samples and only trace 
amounts of metabolites were recovered in urine. Olmesartan was mainly 
excreted as such (65-90 % to feces) and undergoes very little metabolism. In 
this study hydrolysis of OM was fast in human liver and intestine S9 fractions 
which was also observed by Ishizuka et al. (2013). The passive permeability 
of OM was notably higher than the permeability of olmesartan. Considering 
these results the low bioavailability could be due to fast formation of 
olmesartan inside enterocytes followed by flux of olmesartan back to 
intestinal lumen. Alternatively the bioavailability could be partly limited by 
low solubility of both the prodrug and APC. 
 
The rate of olmesartan formation in dog IS9 was lower compared to 
corresponding human factors. This is likely to be explained with the lack of 
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carboxymethylenebutenolidase expression in dog intestine (Ishizuka et al. 
2013; Fig 19). The observed olmesartan formation in dog IS9 would thus be 
contributed to other enzymes such as paraoxonase. 
 
As discussed above, the rate of CC in vitro activation was very high. E.g. in 
dog LS9 almost half of the prodrug had been hydrolyzed to candesartan in the 
t0 sample (during maximum of 20 second mixing). Nonenzymatic hydrolysis 
should be of similar rate in all of the biological matrices regardless of the 
species. However, hydrolysis was observed in t0 samples of rat and human 
IS9, but not observed in dog IS9 t0 –samples which does not support theory of 
chemical instability. Moreover candesartan cilexetil was stable in buffer.  
 
In the study by Ishizuka et al. (2013) CC hydrolysis was mainly observed in 
liver microsomes and very little CC hydrolysis was detected in the microsomal 
or cytosolic fractions of dog, rat or human intestine (Figure 9). Thus it is very 
interesting why in this study rapid hydrolysis was observed in intestinal S9 
fractions of these species (Figures 35 and 36). Chemical instability is unlikely 
to explain this as CC was stabile in buffer and no candesartan was formed in 
buffer. In the study by Ishizuka et al. (2013) recombinant human CES2 was 
able to hydrolyze CC at slow rate (much slower than hCES1). Given the fact 
that S9 protein concentration was 9-fold in the current study compared to 
what was used by Ishizuka et al. it might be possible that the observed 
hydrolysis was CES2 mediated. However dog IS9 fraction should not contain 
neither carboxylesterase (Taketani et al 2007), consequently the candesartan 
formation in dog IS9 fractions cannot be explained with CES2 mediated 
activation.  
 
Ishizuka et al. (2013) terminated the incubations by addition of ice-cold 
acetonitrile containing 0.25% of formic acid. The purpose of formic acid was 
to prevent nonenzymatic degeneration of the prodrugs (OM and CC). In 
current study plain ice-cold acetonitrile was used to terminate incubations. 
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Thus it is possible that the differences in the results and hydrolysis in t0 
samples were due to chemical instability, although this does not explain why 
hydrolysis was not observed in buffer. By using lower protein concentrations 
in CC and OM incubation should produce lower activation rates and thus 
prove the instability to be enzymatic, not chemical and moreover give more 
accurate rates of bioactivation. 
 
In all human matrices studied, the first deacetylation of famciclovir was of 
higher rate than the second deacetylation. The same observation was 
reported by Vere Hodge et al. (1989). The oral bioavailability of penciclovir 
formed form famciclovir is ca. 75%, compared to 4% in the case of the plain 
penciclovir (Jarvest et al. 1998). The in vitro rate of penciclovir formation in 
this study was very slow, but still clinically relevant concentrations are 
achieved in vivo. However aldehyde oxidase (AO) activity is generally 
underestimated by scaling in vitro results with established methods, most 
likely due to lability of AO in vitro or because of the expression of AO outside 
the liver (Zientek et al. 2010). Consequently what looks minor in vitro can be 
clinically sufficient in vivo. 
 
14.3 General discussion 
 
The methods for studying in vitro bioactivation of prodrugs found in literature 
are mainly based on prodrug formation in liver microsomes and plasma 
(Malmborg and Ploeger 2013). In vitro bioactivation in other tissues is 
studied, but is not routinely used during lead optimization. Considerable 
amount of bioactivation and other metabolism is able to occur in other tissues 
such as the intestine. Thus depending on the goal of prodrug strategy and the 
route of administration, prodrug formation and APC stability should be 
studied in other relevant matrices such as intestinal S9, GI fluids etc. 
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Apart from few exceptions, microsomes or microsomes parallel to cytosols 
have been more widely than S9 fractions (Fujiyama et al. 2010; Ishizuka et 
al. 2010; Malmborg and Ploeger 2013). However cytosolic fractions of cells 
(present in S9 fraction) contain enzymes contributing to bioactivity of 
prodrugs (Ishizuka et al. 2013; Zientek et al. 2010). Unless there is any 
specific need to study microsomes and cytosols separately, S9 fractions could 
be used instead. S9 fractions provide more comprehensive range of 
bioactivating enzymes. 
 
When designing sequential/parallel mixed-type prodrugs the formation of 
intermediate metabolites in relative matrices is also important to study. This 
is well demonstrated in this study. Monocarbamate terbutaline was not 
measured from the samples. As no terbutaline was formed in higher 
concentration it would be easy to make a false assumption that bioactivation 
of bambuterol would not occur in plasma or in combinatorial matrices. 
Similarly if only famciclovir and penciclovir were to measure, one could make 
a false conclusion of nonproductive metabolism based on the data. Of course 
the detection of intermediate metabolites becomes more complicated when 
mixed-type prodrug is not attended. For this reason it would be essential to 
perform in vitro metabolite screening studies for prodrugs parallel to the in 
vitro bioactivation studies prescribed in this study. 
 
Current studies on estimating the effect of plasma protein binding on drug 
metabolism rely on in silico models which combine data of plasma protein 
binding studies and from in vitro metabolic stability. In incubations with 
combinational matrices of S9 fraction with plasma, the plasma protein 
binding could in theory slow down hydrolysis of the prodrug compared to plain 
S9 fractions. E.g. for prodrugs targeting reduced first-pass liver metabolism, 
the plasma protein binding could in theory increase bioavailability (as long 
as bioactivation occurs in some other tissue).  Olmesartan and bambuterol 
were incubated in these combinatorial matrices, but the reduction in the rates 
78 
 
were not observed, assumable because both of these prodrugs were also 
hydrolyzed in plasma alone. Consequently with the test compounds studied 
it was not possible to prove if plasma combined with liver S9 fractions could 
be used in vitro to estimate how plasma protein binding effects rates of 
bioactivation or nonproductive metabolism. However this may be useful to 
study in the future. 
 
The prodrug strategy most certainly adds complexity to pharmacokinetics of 
drug molecules. For new chemical entities affinity to the target protein as 
well as suitable drug-like properties are required. The prodrug strategy is 
usually introduced to overcome difficulties in these properties. The promoiety 
should thus contain structures that enhance the drug-like property in 
question. Optimizing the promoiety/linker as a substrate for a specific enzyme 
is a possible way to achieve sufficient rates of APC formation in desired 
compartments of the body. As long as the distribution of this enzyme is known 
the bioactivation is more likely to take place at desired compartments of the 
body. Finding of novel bioactivating enzymes increases the possibilities of 
prodrug strategies. 
 
To obtain comparable APC concentration in preclinical species and human, 
the distribution and activity of bioactivating enzymes should also be 
comparable to human. E.g. since AO is not expressed at all in canines, dog is 
not suitable species for preclinical studies if the prodrug requires AO 
mediated bioactivation (Klecker et al. 2006; Garattini et al. 2008). 
Additionally, the enzyme(s) responsible for bioactivation of prodrugs can vary 
between species. Data from in vitro prodrug activation studies helps in the 
selection of preclinical species.  
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15. CONCLUSION 
 
The choice of in vitro matrices used in bioactivation studies is highly 
dependent on the aim of the prodrug strategy. The target defines the in vivo 
compartments of preferred and non-preferred bioactivation. The stability of 
prodrugs investigated should be tested in all of the relative in vitro matrices 
(intestine, plasma, liver, target tissue etc.). The clinical efficacy of the 
prodrugs used in this study have been proven, but they showed very different 
rates of bioactivation in vitro in this study. Therefore clinically relevant 
formation of APC can be achieved with both high and low rate of in vitro 
bioactivation.   
 
Especially if the site of bioactivation is likely to take place in metabolic 
tissues, the rates of prodrug formation should be studied with and without 
cofactors. This enables the identification of nonproductive metabolism. 
Metabolite screening studies could be used for identification of intermediate 
metabolites required for the route of bioactivation of multiple prodrugs and 
to identify the possible non-productive metabolites formed. 
 
Prodrug strategy offers interesting opportunities to overcome difficulties in 
drug discovery. However, the problems associated with the use of prodrug 
strategy, raise the question of: When to use prodrug strategy? For future 
perspectives this question is very important to be answered. 
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APPENDIX I: Prodrug strategy approach 
 
Low Solubility
→ polar 
promoieties
Phosphates
I.V administration:
- bioactivation in: 
plasma, liver
-Renal clearance of the 
prodrug?
-Rate of APC 
formation? IR or 
prolonged release?Oral administration:
-Stability in 
intestinal fluids 
and homogenates
-Fast rate of 
hydrolysis in the 
intestine desired
APC requirements:
- Dose number >100
- BSC class II
Aminoacid 
-Hydrolysis in 
Intestinal matrice: S9, 
or homogenates
→ Hydrolysis in liver 
S9, if no hydrolysis in 
intestinal matrices
-Solubility in 
intestinal pH
-Change in passive 
permeability: Caco-2; 
PAMPA
- Active tansportation, 
substrate for PEPT1 
or other transporters?
-Species differences
Low 
absorbtion 
→ Increasing 
active 
transportation
/masking polar 
functionalities
Amino acids
Lactones
Activation in 
Liver S9/plasma 
(Substrate to 
PONs?)
Esters
Release of APC in 
intestinal/liver S9 
and/or plasma
-Activation in 
intestinal S9: APC 
substrate to efflux?
-Nonproductive 
metabolism in 
IS9/LS9?
-Species differences
Carbamates
-Hydrolysis in Plasma, 
Lives S9, Intestinal S9
-Inhibition of own 
activation?
-Permeability 
improved?
-Species differences?
-Too enzymatically 
stable?
-Nonproductive 
metabolism
-Species differences
Other 
lipophilic 
promoieties
Hydrolysis in intestine 
and liver S9.
Stability in intestinal 
fluids
Problem 
adressed
Possible 
promoieties
Matrices used
Other things to 
consider
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Excessive first-
pass metabolism
→ Masking a 
metabolic hot 
spot 
-Carbamates
-Plasma (ButChE)
-Whole blood (AcChE in 
erythrocytes)
-Stability in Liver S9 
and/or intestinal S9 
(depending on the site  
of firs-pass metabolism) 
-potentially slow release 
of APC (built-in depot)
-Potential inhibition of 
BuChE
-Plasma protein binding 
(Effect on extraction 
ratio)
-Stability in 
metabolictissues
-nonproductive 
metabolism
-Other chemically 
stable promoieties 
that can be 
incorporated into 
the metabolic hot 
spot with 
enzymatically 
cleavable linker
-Stability of prodrug in 
LS9 and IS9 fractions 
(with and without 
cofactors - bioactivation 
vs nonproductive 
metabolism
-in vitro bioactivation in 
nonmetabolic matrices 
(plasma/target tissue/ 
intestinal fluids etc.)
-Plasma protein binding 
(Effect on extraction 
ratio)
-The enzymes targeted 
with the prodrug 
strategy 
-Ia,IIb or IIc preferred 
prodrug classes
-nonproductive 
metabolism
Problem adressed
Possible 
promoieties
Matrices used
Other things to 
consider
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APPENDIX II: UPLC and MS/MS methods used in analysis 
 
UPLC methods used. rt = retention time.  
Analyte Column flow rate 
(ml/min) 
rt 
(min
) 
gradient; time (min); A/B; 
A = 0,1% HCOOH,  
B = ACN;  
Bambuterol BEH C-18, 1,7µm 2,1 x 
100µm (Waters, USA) 
0,4 1,2 initial; 90/10         
0-0,3; 80/20           
0,3-1,5; 50/50        
1,5-1,8 10/90         
1,8-2,9; 10/90        
2,9-3,0; 90/10        
3,0-3,5; 90/10        
Terbutaline BEH C-18, 1,7µm 2,1 x 
100µm (Waters, USA) 
0,4 0,6 
Olmesartan 
medoxomil 
BEH shield RP18, 1,7µm 
2,1 x 100µm  (Waters, 
USA) 
0,4 2,5 Initial; 70/30 
0-1,4; 70/30 
1,4-1,6; 60/40 
1,6-2,0; 20/80 
2,0-2,5; 20/80 
2,5-3,0; 70/30 
3,0-3,8 70/30 
Olmesartan BEH shield RP18, 1,7µm 
2,1 x 100µm  (Waters, 
USA) 
0,4 1,1 
Candesartan 
cilexetil 
BEH shield RP18, 1,7µm 
2,1 x 100µm  (Waters, 
USA) 
0,4 2,4 initial; 70/30 
0-0,7; 70/30            
0,7-0,9; 60/40         
0,9-1,3; 20/80         
1,3-2,0; 20/80         
2,0-2,1; 70/30         
2,1-3,0; 70/30         
Candesartan BEH shield RP18, 1,7µm 
2,1 x 100µm  (Waters, 
USA) 
0,4 1,9 
Famciclovir BEH shield RP18, 1,7µm 
2,1 x 100µm (Waters, 
USA) 
0,3 1,50 initial; 90/10 
0-0,4; 90/10            
0,4-0,6; 70/30         
0,6-1,1; 30/70         
1,1-1,7; 30/70         
1,7-1,8; 90/10         
1,8-3,0; 90/10         
Desacety 
famciclovir 
BEH shield RP18, 1,7µm 
2,1 x 100µm  (Waters, 
USA) 
0,3 0,93 
6-deoxy-
penciclovir 
BEH shield RP18, 1,7µm 
2,1 x 100µm  (Waters, 
USA) 
0,3 0,76 
Penciclovir BEH shield RP18, 1,7µm 
2,1 x 100µm  (Waters, 
USA) 
0,3 0,82 
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MS/MS methods used. M+H = mole mass of ionized molecule, DP = 
declustering potential, CE = Collition energy, CXP = collision cell exit 
potential, TEM = ion source temperature, GS1 = nebulizer gas, GS2 = heater 
gas, Cur = curtain gas and CAD = collision gas.  
Analyte M+H Transition DP CE CXP TEM GS1 GS2 CUR CAD 
Bambuterol 368 368312 70 21 20 400 50 50 20 3 
Terbutaline 226 226152 60 24 10 400 50 50 20 3 
Olmesartan 
medoxomil 
559 559429  55 24 25 400 30 50 30 5 
Olmesartan 447 447207 70 30 17 400 30 50 30 5 
Candesartan 
cilexetil 
612 612423 60 20 31 550 40 50 14 3 
Candesartan 441 441263 50 18 16 550 40 50 14 3 
Famciclovir 322 322 136 80 35 12 600°C 60 50 15 6 
Desacetyl 
famciclovir 
280 280136 80 30 12 600°C 60 50 15 6 
6-deoxy-
penciclovir 
238 238136 20 27 12 600°C 60 50 15 6 
Penciclovir 254 254152 70 30 10 600°C 60 50 15 6 
 
 
